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Abstract: Spinal cord injury triggers irreversible loss of motor and sensory functions. Numerous
strategies aiming at repairing the injured spinal cord have been studied. Among them,
the use of bone marrow-derived mesenchymal stem cells (BMSCs) is promising.
Indeed, these cells possess interesting properties to modulate CNS environment and
allow axon regeneration and functional recovery. Unfortunately, BMSC survival and
differentiation within the host spinal cord remain poor, and these cells have been found
to have various adverse effects when grafted in other pathological contexts. Moreover,
paracrine-mediated actions have been proposed to explain the beneficial effects of
BMSC transplantation after spinal cord injury. We thus decided to deliver BMSC-
released factors to spinal cord injured rats and to study, in parallel, their properties in
vitro. We show that, in vitro, BMSC-conditioned medium (BMSC-CM) protects neurons
from apoptosis, activates macrophages and is pro-angiogenic. In vivo, BMSC-CM
administered after spinal cord contusion improves motor recovery. Histological analysis
confirms the pro-angiogenic action of BMSC-CM, as well as a tissue protection effect.
Finally, the characterization of BMSC-CM by cytokine array and ELISA identified
trophic factors as well as cytokines likely involved in the beneficial observed effects. In
conclusion, our results support the paracrine-mediated mode of action of BMSCs and
raise the possibility to develop a cell-free therapeutic approach.
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Spinal cord injury triggers irreversible loss of motor and sensory functions. Numerous strategies 
aiming at repairing the injured spinal cord have been studied. Among them, the use of bone marrow-
derived mesenchymal stem cells (BMSCs) is promising. Indeed, these cells possess interesting 
properties to modulate CNS environment and allow axon regeneration and functional recovery. 
Unfortunately, BMSC survival and differentiation within the host spinal cord remain poor, and these 
cells have been found to have various adverse effects when grafted in other pathological contexts. 
Moreover, paracrine-mediated actions have been proposed to explain the beneficial effects of BMSC 
transplantation after spinal cord injury. We thus decided to deliver BMSC-released factors to spinal 
cord injured rats and to study, in parallel, their properties in vitro. We show that, in vitro, BMSC-
conditioned medium (BMSC-CM) protects neurons from apoptosis, activates macrophages and is pro-
angiogenic. In vivo, BMSC-CM administered after spinal cord contusion improves motor recovery. 
Histological analysis confirms the pro-angiogenic action of BMSC-CM, as well as a tissue protection 
effect. Finally, the characterization of BMSC-CM by cytokine array and ELISA identified trophic 
factors as well as cytokines likely involved in the beneficial observed effects. In conclusion, our 
results support the paracrine-mediated mode of action of BMSCs and raise the possibility to develop a 






















Spinal cord injury (SCI) is characterized by the primary lesion, rapidly followed by a cascade 
of cellular and molecular events that trigger the development of the secondary lesion, known 
to be deleterious for axonal regeneration and functional recovery. This worsening of the 
primary lesion is characterized by inflammatory reactions [1,2], free radical production [3], 
glutamate excitotoxicity [4], neuronal death and oligodendrocyte apoptosis [5-7]. With time, 
necrosis spreads to adjacent tissues and a cystic cavity appears [8-10]. Moreover, the initiated 
spontaneous axonal regeneration is repressed by the inhibitory environment composed of 
astroglial scar, and myelin-derived inhibitory molecules [11].  
In this context, numerous experimental studies have been performed to improve functional 
recovery, focusing on various parameters: control of inflammation [12,13], rescue of neural 
tissue [14,15], stimulation of axonal regeneration by modulation of the lesioned environment 
[16-18] or promotion of remyelination [19,20]. Among the developed strategies, cell 
transplantation aims at replacing lost cells or producing beneficial effects at the lesion site. 
Among them, olfactory ensheathing cells, schwann cells, macrophages, fibroblasts, neural 
stem cells or BMSCs have been transplanted in various spinal cord injured contexts [21-29].  
BMSCs are adult stem cells easily isolated from the bone marrow. BMSC transplantations 
have been widely studied in the context of SCI, and have proven beneficial effects on various 
aspects: inflammation, apoptosis, axonal regrowth, angiogenesis, tissue sparing, astroglial 
scar, and motor recovery [21,23,24,30-34]. Nevertheless, BMSC transplantations have some 
disadvantages: they do not persist within the host injured spinal cord after transplantation 
[35,36], and  have a limited ability to replace lost cells [23,37,38]; finally, when used in other 
pathological contexts, BMSC transplants can have various adverse effects [39-44].  
It is well known that BMSCs secrete a large variety of molecules and many studies have 
shown beneficial impact of these BMSC-released factors in different models [45-48]. Thus, 
we decided to study the effects of molecules secreted by BMSCs in an adult rat SCI model, 
using rat BMSC-conditioned medium (BMSC-CM). This original strategy constitutes a 
multifactorial treatment that could act on many aspects of SCI physiopathology, avoiding all 
disadvantages and ethical problems related to the use of cells.  
The aim of this study is to evaluate the effect of BMSC-CM on secondary processes involved 
in lesion extension after SCI. In vitro experiments were run in parallel to assess the potential 
beneficial properties of BMSC-CM on apoptosis, angiogenesis and inflammation.  
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II. MATERIALS & METHODS 
 
II.1. BMSC culture and BMSC-CM preparation 
BMSCs were obtained from the bone marrow of femurs and tibias of adult Wistar rats 
and characterized as previously described [21]. After having pooled cells from different 
donors, BMSCs were expanded in DMEM (Invitrogen) containing 4.5 g/L glucose, 0.58 g/L 
L-glutamine and 0.11 g/L pyruvate, supplemented with 10% non-heat inactivated fetal bovine 
serum (FBS, Invitrogen) and 100 I.U./ ml penicillin and 100 µg/ml streptomycin (Invitrogen). 
Medium was changed twice a week, and cells were passaged when 90% of confluence was 
reached. 
BMSC identity is confirmed on the basis of morphological criteria, plastic adherence and 
specific surface antigen expression: CD90(+), CD271(+), CD45(-) and CD11b(-). 
Differentiation ability of BMSCs was also evaluated after induction using specific media as 
previously described [97]. Oil Red O and Alizarin Red S stainings (Sigma-Aldrich) were used 
to assess adipogenic and osteogenic differentiation. 
BMSC-CM was generated as follows: 90% confluent, passage 2-4 BMSCs in T75 
tissue culture flask, were washed 3 times with phosphate-buffered saline (PBS) and 
transferred to a serum-free DMEM culture medium without phenol red during 48 h. CM from 
different flasks were harvested and pooled. Then, CM were concentrated 40 times by 
centrifugation at 4000g for 15 min at 13°C, using 10-kDa MW cut-off filter units (Millipore). 
We consistently obtained, from 10 ml starting volumes, filtrate volumes of about 250 µl. 
Filter units were used only one time to avoid membrane saturation. Concentrated CM were 
then sterilized on 0.22 µm filters (Millipore), and stored at -80°C until use. The mean protein 
concentration of BMSC-CM is of 1.2-1.5 mg/ml. BMSC-CM was divided into small aliquots 
(500 µl-1 ml) before freezing to avoid repeated freeze/thaw cycles. Each aliquot was visually 
inspected before use to verify absence of precipitate (meaning a possible loss of protein 
function). There was no difference in protein concentration between fresh and freezed CM. As 
additional control, we also tested the stability of BMSC-CM by keeping it for 7 days at 37°C 
before assessing its anti-apoptotic property using the protocol described below.  






II.2. Cerebellar granule neuron culture and apoptosis 
CGNs were obtained from 4- to 7-day-old Wistar rats, and dissociated as previously 
described [98]. Cells were seeded at a density of 125,000 cells/well. A purity of 95% was 
obtained and confirmed by double GFAP/3-tubulin immunostaining. Three to four hours 
after seeding, CGNs were treated overnight with one of the following serum free media to 
induce apoptosis: (1) CGN culture medium, (2) CGN culture medium + 25% BMSC-CM, (3) 
CGN culture medium + 50 ng/ml TNF(Invitrogen), (4) CGN culture medium + 50 ng/ml 
TNF + 25% BMSC-CM. This proportion of BMSC-CM was chosen because pilot 
experiments showed the same effect when 25% or 50% of BMSC-CM were used. 25% was 
thus the better compromise to obtain an effect without neither affecting neuronal survival nor 
wasting BMSC-CM. Cells were then fixed in buffered 4% paraformaldehyde (PFA) for 10 
min. Apoptosis was evaluated with the TUNEL method, according to the manufacturer’s 
protocol (Roche). Cells were then counterstained with DAPI and mounted on glass slides. 
Photomicrographs of 20 random fields per experimental condition were taken (Olympus 
AX70) at 40x magnification.  
For each condition, the total number of apoptotic cells was reported to the total number of 
cells within the 20 fields. Experiment was repeated 3 or 4 times. The results are expressed as a 
mean apoptotic rate in percent.  
 
II.3. Ex-vivo aortic ring assay 
Rat aortic rings were cultured in three dimensional type-I collagen gels as described by 
Sounni et al. [99]. The following culture conditions were tested:  5% BMSC-CM, 5% control 
medium, 20 ng/ml rat VEGF with or without 1 µg/ml anti-rat VEGF (PeproTech). This 
proportion of BMSC-CM was chosen to limit medium dilution that could affect neovessel 
regrowth and because it already triggered a strong response. Aortic rings were cultured for 9 
days at 37°C in 5% CO2. Photomicrographs were captured, with a Zeiss phase contrast 
microscope at 2.5x magnification (Axiovert 25). A minimum of 3 aortic explants were used 
per experimental condition and experience was repeated at least 3 times. Quantification was 







II.4. Macrophage culture and activation  
Rat macrophage cell line (CRL2192) from ATCC was expanded in Ham’s F-12K 
medium (Invitrogen) supplemented with 15% heat inactivated FBS. Cells were transferred to 
Petri dishes (Falcon) at a density of 2 x 10
5
 cells/ml in the presence of Ham’s F-12K/FBS 
supplemented with: (1) 25% control medium, (2) Lipopolysaccharides (LPS) + Interferon- 
(IFN, (3) LPS + IFN + 25% BMSC-CM and (4) LPS + IFN + IL-4 + IL-13. LPS from 
Escherichia coli 0111:B4 (Sigma-Aldrich) and IFN (Millipore) were respectively used at a 
final concentration of 10 and 2 ng/ml. IL-4 and IL-13 (R&D Systems) were used at a final 
concentration of 10 ng/ml each. Proportion of 25% BMSC-CM was chosen for the same 
reason as for apoptosis experiment. After 24 h at 37°C, adherent macrophages were detached 
and cells and supernatants were collected. Cells were counted to normalize the cytokine 
concentration. Supernatants were centrifuged at 200g to eliminate cells and the cytokine 
contents were analysed by ELISA. Media without macrophages were used as controls to 
remove cytokines that could come from serum and/or BMSC-CM. Experiment was repeated 2 
to 4 times. 
 
II.5. ELISA and antibody array 
ELISA were used to assess i) the amounts of NGF, BDNF, IL-1, IL-6, TNF and IL-
10 in BMSC-CM, as well as ii) the amounts of IL-1, IL-6, TNF and IL-10 in the 
macrophage culture supernatants, according to the manufacturer’s recommendations (R&D 
Systems). For macrophage supernatant, values were related to 100,000 cells. Samples were 
run in duplicate for each experiment, and macrophage experiment was repeated 2 or 4 times. 
For BMSC-CM, samples were run in duplicate for each experiment, and experiment was 
repeated 2 to 13 times, according to the factor. Final results are expressed as a mean 
concentration in cytokine.  
In parallel, a biotin label-based rat antibody array (RayBiotech) coated with 90 antibodies was 
used to obtain a broad view of molecules present in BMSC-CM. Three conditioned media 
from passage 3 BMSC cultures were tested. 
 
II.6. Animal model 
A total of 40 adult female Wistar rats (200g) from the Animal Facility of the University of 
Liege were used. Rats were treated in strict accordance with protocols approved by the Ethical 
Commission for animal use of the University of Liege, and all efforts were made to minimize 
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suffering. Rats were housed in individual cages from 7 days before the experiment, in a 12 h 
light/dark cycle, and in a temperature-controlled environment with access to food and water 
ad libitum. Animals were randomly divided into 4 experimental groups: BMSC-CM treated 
and control animals, sacrificed 1 or 6 weeks after SCI. 10 animals were studied in each group. 
 
II.7. Contusion injury and BMSC-CM/control medium administration 
Contusion SCI was induced with the « Infinite Horizons Spinal Cord Impactor IH-
0400 » from Precision Systems and Instrumentation, LLC, Version 5.0., USA. Rats were 
deeply anaesthetized by inhalation of a mixture O2 (N25) with 5% isoflurane, anaesthesia 
being maintained with 2-3% isoflurane during surgery (Forene, Abbott).  
The skin was incised to expose the thoracic vertebral column and a T10 laminectomy was 
performed. After stabilization of the spinal column, contusion lesion was performed using a 
250 kilodynes force of impact. Dura was opened at the level of the lesion and 10 µl of BMSC-
CM or control medium were directly dropped with a Hamilton syringe onto the lesion. A 
mini-osmotic pump (model 1007D, ALZET, flow rate: 0.5 µl/ h/ 7 days) filled with BMSC-
CM or control medium and linked to a catheter was then implanted to deliver the treatment at 
the lesion site. Muscles and skin were sutured. After 1 week, rats allowed to survive for 42 
days were briefly re-anaesthetized to remove the empty pump, in order to avoid inflammation. 
Bladder function was assessed every day and manually emptied until rats regained control.  
 
II.8. Neurological function evaluation 
Two behavioural tests were used after SCI to assess motor performances of rats: the 
Basso, Beattie and Bresnahan (BBB) open-field test [101] consisting of a 21 point rating 
scale, and the grid navigation test with a 5 point scale [102]. All rats were accustomed to both 
tests 1 week before SCI. Two independent experienced individuals carried out all evaluations 
on a blind basis. 
 
II.9. Euthanasia and histological procedures 
After a deep anaesthesia with intraperitoneal injection of pentobarbital (200mg/kg, 
Nembutal, CEVA Santé Animale), rats were transcardially perfused with 300 ml cold saline 
containing 0.01% heparine (LEO Pharma), then with 500 ml cold buffered 4% PFA in 0.1M 
PBS (pH 7.4), 1 or 6 weeks post-injury. Spinal cords were dissected out, post-fixed for 24 h in 
4% PFA at 4°C and cryoprotected for 48 h in a 30% sucrose buffer at 4°C. Serial, longitudinal 
(20µm thick) and transverse (25µm) sections were performed on, respectively, 15 mm-long 
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and 10 mm-long tissue blocks centred on the lesion site. 1 out of 5 transversal sections were 
preserved. Inflammation and angiogenesis were studied on rats sacrificed 1 week after SCI 
(N=10/group), using respectively CD11b and RECA-1 (Rat Endothelial Cell Antigen) 
immunostainings, on 3 longitudinal sections/animal. Axonal regeneration, astroglial scar 
formation and cavitation were studied on rats sacrificed 6 weeks after SCI. Axonal 
regeneration and astrogliosis were evaluated by immunohistology using antibodies against 
Neurofilaments (NF) and Growth-associated protein 43 (GAP-43) for axons and Glial 
fibrillary acidic protein (GFAP) for astrocytes, on 3 longitudinal sections/animal (N=4/group). 
Finally, cystic cavity extension was measured after Luxol-fast blue/ periodic acid - Schiff / 
hematoxylin staining on 6 transverse sections/animal (N= 6/group).  
The following antibodies were used: Primary antibodies: mouse anti-NF200 (1:400, 
Sigma-Aldrich); rabbit anti-GAP-43 (1:1000, Millipore); mouse anti-GFAP (1:400, Sigma-
Aldrich), mouse anti-CD11b (1:1000, AbD Serotec); mouse anti-RECA-1 (1:200, AbCam). 
Secondary antibodies: biotinylated horse anti-mouse IgG and biotinylated goat anti-rabbit 
IgG (1:500, Vector Laboratories). For anti-NF/GAP-43/GFAP/CD11b/RECA-1, sections 
were processed as previously described [21], except fixation in acetone and incubation in 
0.5% H2O2 for RECA-1 antibody. 
 
II.10. Image analysis 
II.10.1. Cystic cavity 
To quantify cavitation along the ventro-dorsal axis, 6 stained sections/rat (N=6/group), 
covering a distance of 1500 µm on either side of the lesion epicentre, were analyzed. Each 
section was observed under microscope (Zeiss, AxioImager Z1) to measure the height of the 
ventro-dorsal extent of the cyst relative to the one of the spinal cord midline (Mercator Pro 
software, Explora Nova). The mean ratio cyst extent / spinal cord extent was calculated for 
each experimental group and expressed as percentages.      
II.10.2. Immunostaining quantification 
To quantify GFAP, NF, GAP-43 and CD11b, 3 longitudinal sections per animal were 
immunostained for each antigen. Bright field images of successive fields at 5x magnification 
were captured to perform a full reconstruction of each section (Leica DM6000B). On these 
photomicrographs, the immunostained area was measured in 3 boxed areas of 3 mm
2
 placed 
as follows: one at the lesion epicentre, one more rostrally (1000 µm from the epicentre) and 
one more caudally (1000 µm from the epicentre) (see diagram). Using analySIS software 
(Olympus), reconstructed photomicrographs were transformed in grey scales. A threshold 
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intensity of staining was applied. The immunostained surface was then measured in each of 











To quantify the blood vessel diameters, RECA-1 immunostained sections were used. 3 
longitudinal sections per animal were used and 3 fields per section were randomly chosen at 
the lesion epicentre. Bright field images at 10x magnification were captured with Zeiss 
microscope (AxioImager Z1). On each field, diameter of 10 blood vessels was measured with 
analySIS software. The blood vessel mean diameter for both experimental groups is 
considered.    
 
II.11. Statistical analysis 
All data were expressed as means ± standard error of the mean (SEM). The 
improvement of motor recovery was analyzed by Generalized Linear Mixed Model (GLMM), 
which evaluates the global evolution of the two experimental groups. Other data were 
analyzed by unpaired Student’s t-test. P-value (p) < 0.05 was considered statistically 
significant. All the tests were conducted using Statistica software (StatSoft), except for 





III.1. Characterization of rat BMSCs 
BMSCs were expanded in plastic dishes in classical in vitro conditions. Cells were 
characterized by their plastic adherence, the expression of specific antigens and their 
multipotency was checked by their differentiation capacity. Cells were used at low passages 
P2, P3 or P4, to work with young cells and avoid senescence-associated effects progressively 






Epicentre Caudal segment 
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(p75NGFr) but didn't express CD45 and CD11b. Under specific induction media, cells 
differentiated into adipocytes and osteocytes (figures 1A-F).   
 
III.2. BMSC-CM protects neurons from apoptosis in vitro 
Cerebellar granule neurons (CGNs) were cultured and submitted to pro-apoptotic conditions: 
serum free medium or tumor necrosis factor alpha (TNF) (50 ng/ml). BMSC-CM was added 
in each condition at a final proportion volume of 25%. After overnight treatment, cells were 
fixed and apoptosis rates evaluated using the Tunel method and a DAPI counterstain. 
Incubation with BMSC-CM significantly decreased apoptotic rates of neurons whatever the 
experimental condition (figure 2): in serum deprivation condition, BMSC-CM decreased 
apoptotic rate by 10% (from 14.8% ± 1.1 to 4.9% ± 0.7) (p=0.0002, Student's t-test) and by 
more than 12% in TNF-induced apoptosis (from 21.2% ± 2.8 to 8.6% ± 0.6) (p=0.0038, 
Student's t-test). Results were identical with the use of BMSC-CM kept for 7 days at 37°C 
before performing the experiment (data not shown). 
 
III.3. BMSC-CM is pro-angiogenic 
As vessel growth favours axonal regrowth after SCI, we assessed the effect of BMSC-CM on 
angiogenesis. Rat aortic rings were incubated 9 days in a specific medium supplemented with 
5% BMSC-CM, 5% control medium (negative control) or recombinant rat vascular 
endothelial growth factor (VEGF, 20 ng/ml; positive control) (figure 3A). Anti-VEGF 
functional antibody (1 µg/ml) was also added to assess a possible role of VEGF in observed 
effects. The number of intersections (Ni) of neovessels as a function of the distance from the 
ring is illustrated on figure 3B. Areas below curves were calculated in order to include both 
parameters: Ni and the maximal distance from the ring reached by the neovessels. BMSC-CM 
induced a strong angiogenic response in comparison to the control (270.5 ± 18.3 vs 119.3 ± 
11) to reach approximately the same level as with VEGF treatment. Anti-VEGF 
administration abolished the pro-angiogenic effect of BMSC-CM (270.5 ± 18.3 vs 125.3 ± 
25.2) and, as expected, of VEGF. The differences were statistically significant between 
BMSC-CM and control medium (p < 0.0001, Student's t-test) and between BMSC-CM and 
BMSC-CM + anti-VEGF (p=0.0003, Student's t-test; figure 3C). This indicates that VEGF is 






III.4. BMSC-CM favours a pro-inflammatory state of macrophages in vitro  
In order to study the effects of BMSC-CM on macrophage phenotype, rat macrophages were 
activated with LPS (10ng/ml) and IFN (2 ng/ml) to simulate the in vivo inflammation that 
follows SCI. Activated macrophages were further incubated with 25% control medium, 25% 
BMSC-CM, or anti-inflammatory cytokines: interleukin 4 and 13 (IL-4 and IL-13) (10 
ng/ml). After 24h, culture media were harvested to assess their content in IL-1, IL-6, TNF 
and IL-10 by ELISA. Each value was normalized for 100,000 cells, and the concentration of 
cytokines present in BMSC-CM or serum was deduced. Without LPS/IFN stimulation, 
100,000 macrophages secreted 3.7 pg/ml ± 0.4 of IL-1, while activated cells secreted 115.5 
pg/ml ± 31.2. Incubation with BMSC-CM significantly increased IL-1 concentration in 
supernatant of activated macrophages from 115.5 pg/ml ± 31.2 to 206 pg/ml ± 19 (p=0.048, 
Student's t-test). The use of IL-4 and IL-13 on activated macrophages reduced slightly the 
secretion of IL-1 to 95.6 pg/ml ± 10.2 (figure 4A). IL-6 and TNF values also show a 
tendency to increase after BMSC-CM treatment, without reaching significant levels of 
differences (figures 4B-C). On the contrary, no secretion of IL-10 was observed (data not 
shown). Thus, BMSC-CM is globally pro-inflammatory on macrophages, as it exacerbates 
their secretion of pro-inflammatory cytokines.  
 
III.5. BMSC-CM characterization   
In order to further characterize BMSC-CM, we performed large antibody arrays (90 proteins) 
as well as ELISA assays. Antibody arrays, performed on 3 distinct BMSC-CM samples 
(figure 5A), reveal the presence of 23 factors involved in either apoptosis, inflammation, 
angiogenesis, oxidative stress, excitotoxicity, all involved in the modulation of the spinal cord 
injured environment  (Table 1).    
ELISA were performed on 4 cytokines: IL-6, IL-1, TNF, IL-10 and 2 neurotrophins: brain-
derived neurotrophic factor (BDNF), nerve growth factor (NGF). The analysis of different 
BMSC-CM demonstrates that NGF and BDNF are present at 356 pg/ml ± 117 and 208 pg/ml 
± 57 respectively, as well as IL-6 at 427 pg/ml ± 168 (figure 5B). IL-1, TNF and IL-10 
were not detected in these samples. 
 
III.6. BMSC-CM improves functional recovery after SCI 
Spinal cord injured animals were submitted to 2 complementary behavioural tests. The Basso, 
Beattie and Bresnahan (BBB) open-field test was used to assess motor skills of rats until 6 
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weeks post-injury (figure 6A). The difference between treated and control groups was 
statistically significant (Injured + BMSC-CM vs Injured + control p=0.0003, Generalized 
Linear Mixed Model). From day 4 after SCI, BMSC-CM treated animals show better scores 
than control animals and this difference was maintained during the study. Score 9 is crucial as 
it indicates the weight support step. The figure shows that this stage is reached by treated 
animals 4 days before control animals. Moreover, control animals never recovered their 
ability to separate toes and to maintain hindpaws in a parallel position at lift off during 
stepping (score of 16). These parameters, successfully performed by treated animals, bear 
witness to a fine recovery of motricity.  
The grid navigation test was used to assess fine motor coordination and movement accuracy 
(figure 6B). Mean scores over time were significantly higher in BMSC-CM treated group 
compared to control group (Injured + BMSC-CM  vs Injured + control p=0.0001, 
Generalized Linear Mixed Model). We noticed that difference between both groups started 
from day 4 post-injury. Score 4, testifying a correct placement on grid bars, was reached only 
by BMSC-CM treated animals.  
 
III.7. BMSC-CM reduces cystic cavity 
The improved motor recovery observed in BMSC-CM treated animals could be explained by 
a reduced extension of the lesion. To investigate this aspect, spinal cord injured transversal 
sections from both experimental groups were performed 6 weeks after injury and stained with 
Luxol-fast-blue / periodic acid - Schiff / hematoxylin. Serial sections were then analyzed to 
quantify the ventro-dorsal extent of the cystic cavity (figures 7A-B).  As spinal cord volume 
can vary over the lesion epicentre, cystic height was related to spinal cord height on the same 
dorso-ventral axis, and ratio expressed in percentages. BMSC-CM treated group shows 
reduced mean values compared to control group (Injured + BMSC-CM: 67.72% ± 3.4 vs 
Injured + control: 83.4% ± 2.1; figure 7C). Difference between BMSC-CM treated and 
control groups was statistically significant (p=0.0029, Student's t-test).    
 
III.8. BMSC-CM is pro-angiogenic in vivo 
Longitudinal spinal cord injured sections from treated and control groups were performed 1 
week post-injury and immunostained for RECA-1. Diameters of blood vessels were measured 
at the lesion epicentre. Blood vessels exhibit larger diameters in BMSC-CM treated animals 
compared to controls (Injured + BMSC-CM: 14.4 µm ± 1.2 vs Injured + control: 6.9 µm ± 
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0.8; figures 8A-B). Difference between both groups was statistically significant (p<0.0001, 
Student's t-test) .  
 
III.9. In vivo, BMSC-CM has no effect on astrogliosis, macrophage invasion and axonal 
regrowth 
To study astrogliosis, longitudinal sections performed 6 weeks after injury were 
immunostained for GFAP. Quantification of the immunostained surface was carried out in 3 
defined areas. This value was related to the total area of each of the 3 zones to express a 
proportion of stained area. We didn't detect any difference between BMSC-CM treated and 
control animals (Student's t-test). After CD11b immunostaining, quantifications were 
performed as described above. Values obtained for BMSC-CM treated and control groups 
were not significantly different (Student's t-test). In order to assess the ability of BMSC-CM 
to favour axonal regrowth after SCI, anti-NF and anti-GAP-43 immunostainings were 
performed. Quantifications didn't reveal any difference between groups, whatever the delay 





Our results show that, in vitro, BMSC-CM provides protection against neuronal apoptosis, is 
pro-angiogenic and confers a pro-inflammatory phenotype to macrophages. In vivo, we 
demonstrate for the first time that BMSC-released molecules are able to reduce cystic cavity 
size along the ventro-dorsal axis at the lesion epicentre, to favour large blood vessel growth 
and to improve locomotor recovery in a spinal cord contusion injury model.  
Many studies suggest that beneficial effects obtained after BMSC transplantation in SCI were 
more likely due to paracrine actions than to effective integration and differentiation of the 
cells within the host tissue [21,23,36,38,50-53]. Our study confirms this hypothesis.  
We decided to deliver factors secreted by BMSCs in the form of concentrated conditioned 
medium (CM), to optimize potential effects. We also chose to use a fraction of this BMSC-
CM that contains factors of a molecular weight > 10 kDa, as this fraction was earlier 
described as beneficial on myocardial infarct size, oxidative stress and apoptosis [54]. 
Moreover, we eliminated serum from the medium because of its poorly defined composition.  
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Two complementary behavioural tests were used to assess recovery of motor functions: BBB 
as a global recovery test, and grid navigation to evaluate more precisely fine motor 
movements. In both tests, control animals show spontaneous recovery after spinal cord 
contusion. The great spontaneous recovery obtained here can also be explained by the type of 
the lesion, which, despite the use of a 250 kdyn force, doesn't severely affect the ventral part 
of the spinal cord, thus preserving white matter tracts [55]. According to the literature, 200 
kdyn already corresponds to a severe injury, but this parameter is also known to vary upon the 
animal weight or strain [56,57]. Despite this fact, BMSC-CM treated rats obtained 
significantly higher scores in both tests compared to control animals. Difference between 
groups started from days 4 to 7, indicating a rapid effect after administration, as also 
described after BMSC transplantation in a model of spinal cord contusion injury [24]. Later 
on, BBB scores continue to improve, with treated rats displaying at each delay higher scores 
compared to controls. In their study, Namiki et al. showed an improvement of inclined plane 
scores one week after BDNF infusion by osmotic pump in a SCI clip model. However, this 
evolution stopped very early after the end of the BDNF treatment [58]. The prolonged effect 
that we obtain may be due to the combined action of several factors present in our CM, with 
maybe redundant molecules with variable bioavailabilities. It is also possible that the cocktail 
of administered factors favours the survival of endogenous cells preserving the tissue from 
further lesion extension.  
In other studies, after BMSC transplantation in contusion or compression models of rat SCI, 
locomotor improvements were also observed during weeks following the graft, with BBB 
scores reaching similar levels. For example, 4 weeks after spinal contusion and BMSC graft, 
Karaoz and colleagues obtain a BBB score of 15 while our treated rats reach the score of 16 at 
the same delay. Also, 3 weeks after BMSC graft in a compression injury model, Quertainmont 
et al. show that rats reach a BBB score of 12 which is even lower to the score of 15 reached in 
the present study [21,24]. This reinforces our hypothesis that BMSC-secreted factors are 
beneficial after SCI and that they improve functional recovery as do BMSC transplants.  
Improved recovery can be a consequence of neural tissue protection, which is favoured by 
angiogenesis. Angiogenesis is indeed known to induce axonal regrowth via the supply of 
oxygen and nutritional factors that helps preserving injured spinal tissue from further 
degradation [59,60]. Moreover, it has been shown that the pro-angiogenic VEGF molecule 
possesses neuroprotective properties [61-63]. This factor is present in BMSC-CM and our in 
vitro data on aortic rings confirm that it is involved in the pro-angiogenic effect. Other factors 
which are known to promote angiogenesis were also detected in BMSC-CM: osteopontin 
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[64,65], matrix metalloproteinase-13 (MMP-13) [66] and fibroblast growth factor-binding 
protein (FGF-BP) [67,68]. In vivo, blood vessels observed at the lesion epicentre of treated 
animals, even if not higher in number, have larger diameters compared to controls, and could 
thus provide, via increased blood flow, more nutritional substances and oxygen to damaged 
tissue, contributing to tissue protection, as already described after thoraco-abdominal 
aneurysm in pigs [69]. Lu et al. have also measured this parameter and their data suggest that 
atorvastatin treatment elicits larger vascular diameter, thus contributing to enhanced regional 
blood flow perfusion and neuron rescue [70]. So, larger diameters of blood vessels seem to be 
associated with a better tissue perfusion, protecting neuronal cells from degeneration. Yet, we 
didn't observe increased axon regeneration in treated spinal cords compared to control ones. 
In the same context, Dray’s study suggests that even if some axons benefit from vascular 
support to accelerate their growth, this support is only transient and limited in time [60].  
Tissue protection could also be related to a reduced apoptosis rate within the injured cord. Our 
data show that BMSC-CM protects neurons from apoptosis in vitro. Neuronal death and 
apoptosis rapidly followed by oligodendrocyte apoptosis are parts of secondary processes 
making the lesion worse. BMSC transplantations have been successfully used to reduce 
apoptotic death in the context of SCI, and associated to a better motor recovery [32]. In this 
study, we demonstrate that BMSC-CM treated spinal cords have a reduced depth of cystic 
cavity, protecting white matter tracts. You et al. demonstrated a positive correlation between 
spared ventral white matter and the final BBB scores of rats [55]. Also, the rubrospinal tract 
in the dorsolateral part and the corticospinal tract located in the dorsal part of the spinal cord 
white matter in rats are particularly important for precise limb movements, and can be 
assessed by grid navigation test [71]. Based on our behavioural data, we can thus conclude 
that the better motor recovery observed in BMSC-CM treated animals is a direct consequence 
of improved tissue sparing.  
Among factors identified in BMSC-CM by cytokine arrays and ELISA, some may also 
contribute to tissue preservation. NGF stimulates the survival of sympathetic and sensory 
neurons, while TIMP-1 (tissue inhibitor of metalloproteinase-1) and CINC-3 (cytokine-
induced neutrophil chemoattractant-3) are neuroprotective [72,73]. BDNF administration 
decreases apoptosis and demyelination in a spinal cord compression model [74] and reduces 
astroglial scar formation [75]. Also, other factors, thus not described here, are known to be 
secreted by rat BMSCs: IGF-1, HGF, TGF-β1, EGF, SDF-1, MIP-1α/β, GM-CSF or FGF-2 
[76,77]. The fact that we didn't find those factors is first due to the fact that some of them 
were not included in our 90-protein array assay. Moreover, BMSC culture conditions may 
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influence their secretome, which would explain why factors described in other studies were 
not detected here and conversely.  
In our model, BMSC-CM doesn’t affect astroglial reactivity. This result could be considered 
as unexpected, as both NGF and BDNF, present in BMSC-CM, are known to reduce reactive 
astrogliosis [75,78]. This discrepancy is likely due to the variable concentrations of these two 
neurotrophins. Also, according to the literature, few studies report any effect of BMSC 
transplantation on astroglial scar development after SCI. This is also the case for axonal 
regeneration, which is rarely reported as associated to improved recovery after BMSC 
transplants [24,79-82]. 
In vitro data on IFN/LPS-activated macrophages show that BMSC-CM further favours their 
pro-inflammatory state, as assessed by their significant increased IL-1 secretion and their 
obvious but non-significant increased IL-6 and TNF production. In parallel, we also show 
that BMSC-CM contains IL-6, which possesses pro-inflammatory properties as well [83,84]. 
In vivo, we didn’t detect any difference between treated and control groups, in the number of 
macrophages that invaded the lesion site 1 week post-injury, as assessed by the total area 
stained for CD11b. Microglia/macrophages present within the lesion exhibited in both groups 
round cell bodies without branching processes, characteristic of "amoeboid" cells, and 
indicative of an activated status. This reactive cell form is associated with neuroprotective 
effects via trophic factor delivery and with phagocytosis that is essential to remove cell and 
myelin debris [23,85-87]. In this context, we hypothesize that BMSC-CM has further 
favoured the activated state of resident microglia and invading macrophages, conferring a 
phenotype beneficial for tissue preservation, without affecting the number of inflammatory 
cells within the lesion. This hypothesis is in accordance with the fact that IL-1 and IL-6 do 
indirectly promote axonal outgrowth [88,89] and protect neurons from death [90,91]. In the 
literature, contradictory results have been described concerning the effect of BMSC 
transplantation on post-injury inflammatory reaction, going from reduced inflammation [92] 
to enhanced macrophage/microglia response [81]. Some authors also suggest that microglial 
activation after SCI is linked to the reduction of the lesion size [23,93]. Indeed, microglia can 
be involved in neuroprotection via secretion of factors such as NGF, IGF-1 (insulin-like 
growth factor-1) or via up-regulation of FGF-2 (fibroblast growth factor-2) in neurons [94-
96]. 
In conclusion, our data show that the use of BMSC-CM in the context of SCI is beneficial and 
not deleterious, and leads to improved motor recovery. This treatment constitutes a novel 
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promising therapeutic perspective in SCI context. More investigations are needed to evaluate 
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Figure 1. BMSC characterization. P4 BMSCs in vitro are immunostained for (A) CD90 and 
(B) CD271 (p75NGFr), but are negative for (C) CD45 and (D) CD11b. Nuclei are labelled 
with Vectashield-DAPI mounting medium. (E) Adipogenic differentiation of P4 BMSC 
revealed with Oil Red O and (F) osteocyte differentiation revealed by Alizarin Red S.  
 
Figure 2. BMSC-CM protects neurons from apoptosis.  
Percentage of apoptotic CGN in serum-free medium or with TNF (50 ng/ml), cultured with 
or without 25% BMSC-CM. BMSC-CM significantly decreases apoptosis. Experiment was 
repeated 3 to 4 times. *** p <0.001; ** p <0.01. 
 
Figure 3. BMSC-CM promotes angiogenesis in vitro.  
(A) Representative photomicrographs of rat aortic rings after 9 days in culture medium 
containing 5% control medium, 5% BMSC-CM or 20 ng/ml of rat VEGF. 
(B) Quantification of number of intersections (Ni) of neovessels treated with 5% control 
medium, 5% BMSC-CM and 20 ng/ml VEGF, with or without 1 µg/ml anti-VEGF.  
(C) Area below curves generated for each condition by the semi-assisted computerized 
quantification. Presence of BMSC-CM significantly favours angiogenesis and this effect is 
mediated by VEGF. Experiment was repeated 3 to 15 times. *** p <0.001.  
 
Figure 4. BMSC-CM stimulates macrophages to secrete pro-inflammatory cytokines. 
Concentration of IL-1 (A), IL-6 (B) and TNF (C) in the supernatant of macrophages 
cultured in various conditions: non-activated, activated with LPS and IFN with or without 
25% BMSC-CM, or with IL-4 and IL-13. BMSC-CM increases significantly IL-1secretion 
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by macrophages and tends also to increase their IL-6 and TNF secretion. Experiment was 
repeated 2 to 4 times. * p <0.05. 
 
Figure 5. BMSC-CM characterization by antibody arrays and ELISA. 
(A) Multiple array membrane incubated with BMSC-CM reveals the presence of hormones, 
proteases, cytokines and trophic factors. Experiment was repeated 3 times.  
(B) Concentrations of NGF, BDNF and IL-6, measured by ELISA, within BMSC-CM. 
Experiment was repeated 2 to 13 times. 
 
Figure 6. Behavioural analysis. 
Evolution of motor scores for BMSC-CM treated and control rats over 6 weeks, as assessed 
(A) by BBB scale and (B) by grid navigation scale. BMSC-CM treated rats obtained 
significantly higher scores compared to control animals. 10 animals per group were studied. 
*** p <0.001. 
 
Figure 7. BMSC-CM reduces lesion extension.   
(A) Illustration of an injured spinal cord transversal section invaded by a cyst. For each 
section, cystic cavity extent (H1) and spinal cord extent (H2) were measured on the median 
axis. Both values were related to express a ratio in percents.  
(B) Photomicrographs of Luxol-fast-blue / periodic acid - Schiff / hematoxylin stained 
sections of BMSC-CM treated and control animals, taken at the lesion epicentre, 6 weeks 
after injury. Cyst extent is shown by an arrow.  
(C) Ratio cyst extent / spinal cord extent of BMSC-CM treated and control animals, 6 weeks 
after injury. BMSC-CM treated animals obtained a ratio significantly reduced compared to 
control group. 6 animals per group were studied. ** p <0.01. 
 
Figure 8. BMSC-CM increases blood vessel diameter within the lesion.  
(A) Mean blood vessel diameter at the lesion epicentre measured on RECA-1 immunostained 
sections from BMSC-CM and control groups 1 week after SCI, illustrated in (B). Blood 
vessels in BMSC-CM treated animals have larger diameters in comparison to control animals. 






Table 1. Factors detected in BMSC-CM. 
 
Phenomena Specific properties Factors 
Apoptosis 
Anti-apoptotic 
VEGF-A, TIMP-1, CINC-3, TIMP-2, 
Osteopontin, Growth Hormone + GHR, 
EG-VEGF/PK1, TAL1A*, FGF-BP, BDNF  
Pro-apoptotic TROY, TRAIL, Fas ligand/TNFSF6  
Inflammation 
Pro-inflammatory 
TLR4 , CINC-3, Osteopontin, EG-
VEGF/PK1, CINC-2, MMP-13, MDC, Fas 
ligand/TNFSF6  
Immunomodulator Osteopontin, CXCR4, MDC  
Angiogenesis 
Pro-angiogenic 
VEGF-A, VEGF-C, Osteopontin, EG-
VEGF/PK1, TAL1A*, MMP-13, FGF-BP  




TIMP-1, CINC-3, Growth Hormone + 
GHR, BDNF  
Anti-neuritotrophic TROY  
Neuronal differentiation TIMP-2  
Modulation of neuronal activity BDNF  
Stress 
Protection from excitotoxicity and 
oxidative stress 
Osteopontin, FGF-BP  
Other 
Cell fate regulation 
TIMP-1, TIMP-2, Hepassocin, Growth 
Hormone + GHR, EG-VEGF/PK1  
Cell survival 
TIMP-1, TIMP-2, Growth Hormone + 
GHR, BDNF  
ECM modulation TIMP-1, MMP-13  
Metabolism 
Insulin degrading enzyme, Insulin, Growth 
Hormone + GHR  
 
Antibody arrays against 90 proteins were performed on 3 different samples of BMSC-CM and 
identified 23 factors likely involved in the modulation of the spinal cord injured environment. 






















N / group 
Astroglial scar 
(GFAP) 
Epicentre 7.4 ± 0.4 6.2 ± 1 0.29 - NS 4 
Rostral 5.8 ± 1.4 7.1 ± 1.7 0.6 - NS 4 
Caudal 5.4 ± 0.9 7.2 ± 2 0.46 - NS 4 
Inflammation 
(CD11b) 
Epicentre 32.1 ± 2 32.2 ± 2.7 0.98 - NS 10 
Rostral 13.1 ± 1.3 15 ± 3.2 0.57 - NS 10 
Caudal 12.1 ± 1.5 17 ± 3.9 0.25 - NS 10 
Axonal regrowth 
1 week post SCI 
(GAP-43) 
Epicentre 8.2 ± 0.9 7.3 ± 1.4 0.57 - NS 10 
Rostral 8 ± 1 7.5 ± 1.6 0.79 - NS 10 
Caudal 7.3 ± 1.1 6.9 ±1.3 0.81 - NS 10 
Axonal regrowth 
6 weeks post SCI 
(GAP-43) 
Epicentre 5.1 ± 1.2 6.2 ± 0.7 0.48 - NS 4 
Rostral 3.1 ± 1.3 4.3 ± 0.6 0.44 - NS 4 
Caudal 1.9 ± 0.6 3.1 ± 0.5 0.21 - NS 4 
Axonal regrowth 
6 weeks post SCI 
(NF) 
Epicentre 5.4 ± 1.6 6.3 ± 1.4 0.71 - NS 4 
Rostral 6.9 ± 2.5 4.8 ± 1.3 0.48 - NS 4 
Caudal 8.9 ± 3.1 6.7 ± 2 0.59 - NS 4 
 
After specific immunostainings (GFAP, CD11b, GAP-43, NF), quantifications of proportion 
(%) of stained area were performed in 3 defined areas. No statistical differences between 




Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Click here to download high resolution image
Figure 5
Click here to download high resolution image
Figure 6
Click here to download high resolution image
Figure 7
Click here to download high resolution image
Figure 8
Click here to download high resolution image
1 
 
Conditioned Medium from Bone marrow-derived Mesenchymal Stem Cells improves 

























 GIGA Neuroscience, Axonal Regeneration and Cephalic Pain Unit, University of Liege, Avenue de 
l'Hôpital, 1, B36, 1st floor, 4000 Liege, Belgium;  
2
 GIGA Cancer, Laboratory of Biology of Tumour and Development, University of Liege, Avenue de 
l'Hôpital, 1, B23, 4th floor, 4000 Liege, Belgium;   
3
 Department of Neuropathology, RWTH University of Aachen, Pauwelsstraße 30, 52074 Aachen, 




Giga Neuroscience / Axonal Regeneration and Cephalic Pain Unit 
Tour de Pathologie B36, +1 
Avenue de l’Hôpital, n° 1 




















Spinal cord injury triggers irreversible loss of motor and sensory functions. Numerous strategies 
aiming at repairing the injured spinal cord have been studied. Among them, the use of bone marrow-
derived mesenchymal stem cells (BMSCs) is promising. Indeed, these cells possess interesting 
properties to modulate CNS environment and allow axon regeneration and functional recovery. 
Unfortunately, BMSC survival and differentiation within the host spinal cord remain poor, and these 
cells have been found to have various adverse effects when grafted in other pathological contexts. 
Moreover, paracrine-mediated actions have been proposed to explain the beneficial effects of BMSC 
transplantation after spinal cord injury. We thus decided to deliver BMSC-released factors to spinal 
cord injured rats and to study, in parallel, their properties in vitro. We show that, in vitro, BMSC-
conditioned medium (BMSC-CM) protects neurons from apoptosis, activates macrophages and is pro-
angiogenic. In vivo, BMSC-CM administered after spinal cord contusion improves motor recovery. 
Histological analysis confirms the pro-angiogenic action of BMSC-CM, as well as a tissue protection 
effect. Finally, the characterization of BMSC-CM by cytokine array and ELISA identified trophic 
factors as well as cytokines likely involved in the beneficial observed effects. In conclusion, our 
results support the paracrine-mediated mode of action of BMSCs and raise the possibility to develop a 






















Spinal cord injury (SCI) is characterized by the primary lesion, rapidly followed by a cascade 
of cellular and molecular events that trigger the development of the secondary lesion, known 
to be deleterious for axonal regeneration and functional recovery. This worsening of the 
primary lesion is characterized by inflammatory reactions [1,2], free radical production [3], 
glutamate excitotoxicity [4], neuronal death and oligodendrocyte apoptosis [5-7]. With time, 
necrosis spreads to adjacent tissues and a cystic cavity appears [8-10]. Moreover, the initiated 
spontaneous axonal regeneration is repressed by the inhibitory environment composed of 
astroglial scar, and myelin-derived inhibitory molecules [11].  
In this context, numerous experimental studies have been performed to improve functional 
recovery, focusing on various parameters: control of inflammation [12,13], rescue of neural 
tissue [14,15], stimulation of axonal regeneration by modulation of the lesioned environment 
[16-18] or promotion of remyelination [19,20]. Among the developed strategies, cell 
transplantation aims at replacing lost cells or producing beneficial effects at the lesion site. 
Among them, olfactory ensheathing cells, schwann cells, macrophages, fibroblasts, neural 
stem cells or BMSCs have been transplanted in various spinal cord injured contexts [21-29].  
BMSCs are adult stem cells easily isolated from the bone marrow. BMSC transplantations 
have been widely studied in the context of SCI, and have proven beneficial effects on various 
aspects: inflammation, apoptosis, axonal regrowth, angiogenesis, tissue sparing, astroglial 
scar, and motor recovery [21,23,24,30-34]. Nevertheless, BMSC transplantations have some 
disadvantages: they do not persist within the host injured spinal cord after transplantation 
[35,36], and  have a limited ability to replace lost cells [23,37,38]; finally, when used in other 
pathological contexts, BMSC transplants can have various adverse effects [39-44].  
It is well known that BMSCs secrete a large variety of molecules and many studies have 
shown beneficial impact of these BMSC-released factors in different models [45-48]. Thus, 
we decided to study the effects of molecules secreted by BMSCs in an adult rat SCI model, 
using rat BMSC-conditioned medium (BMSC-CM). This original strategy constitutes a 
multifactorial treatment that could act on many aspects of SCI physiopathology, avoiding all 
disadvantages and ethical problems related to the use of cells.  
The aim of this study is to evaluate the effect of BMSC-CM on secondary processes involved 
in lesion extension after SCI. In vitro experiments were run in parallel to assess the potential 
beneficial properties of BMSC-CM on apoptosis, angiogenesis and inflammation.  
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II. MATERIALS & METHODS 
 
II.1. BMSC culture and BMSC-CM preparation 
BMSCs were obtained from the bone marrow of femurs and tibias of adult Wistar rats 
and characterized as previously described [21]. After having pooled cells from different 
donors, BMSCs were expanded in DMEM (Invitrogen) containing 4.5 g/L glucose, 0.58 g/L 
L-glutamine and 0.11 g/L pyruvate, supplemented with 10% non-heat inactivated fetal bovine 
serum (FBS, Invitrogen) and 100 I.U./ ml penicillin and 100 µg/ml streptomycin (Invitrogen). 
Medium was changed twice a week, and cells were passaged when 90% of confluence was 
reached. 
BMSC identity is confirmed on the basis of morphological criteria, plastic adherence and 
specific surface antigen expression: CD90(+), CD271(+), CD45(-) and CD11b(-). 
Differentiation ability of BMSCs was also evaluated after induction using specific media as 
previously described [97]. Oil Red O and Alizarin Red S stainings (Sigma-Aldrich) were used 
to assess adipogenic and osteogenic differentiation. 
BMSC-CM was generated as follows: 90% confluent, passage 2-4 BMSCs in T75 
tissue culture flask, were washed 3 times with phosphate-buffered saline (PBS) and 
transferred to a serum-free DMEM culture medium without phenol red during 48 h. CM from 
different flasks were harvested and pooled. Then, CM were concentrated 40 times by 
centrifugation at 4000g for 15 min at 13°C, using 10-kDa MW cut-off filter units (Millipore). 
We consistently obtained, from 10 ml starting volumes, filtrate volumes of about 250 µl. 
Filter units were used only one time to avoid membrane saturation. Concentrated CM were 
then sterilized on 0.22 µm filters (Millipore), and stored at -80°C until use. The mean protein 
concentration of BMSC-CM is of 1.2-1.5 mg/ml. BMSC-CM was divided into small aliquots 
(500 µl-1 ml) before freezing to avoid repeated freeze/thaw cycles. Each aliquot was visually 
inspected before use to verify absence of precipitate (meaning a possible loss of protein 
function). There was no difference in protein concentration between fresh and freezed CM. As 
additional control, we also tested the stability of BMSC-CM by keeping it for 7 days at 37°C 
before assessing its anti-apoptotic property using the protocol described below.  






II.2. Cerebellar granule neuron culture and apoptosis 
CGNs were obtained from 4- to 7-day-old Wistar rats, and dissociated as previously 
described [98]. Cells were seeded at a density of 125,000 cells/well. A purity of 95% was 
obtained and confirmed by double GFAP/3-tubulin immunostaining. Three to four hours 
after seeding, CGNs were treated overnight with one of the following serum free media to 
induce apoptosis: (1) CGN culture medium, (2) CGN culture medium + 25% BMSC-CM, (3) 
CGN culture medium + 50 ng/ml TNF(Invitrogen), (4) CGN culture medium + 50 ng/ml 
TNF + 25% BMSC-CM. This proportion of BMSC-CM was chosen because pilot 
experiments showed the same effect when 25% or 50% of BMSC-CM were used. 25% was 
thus the better compromise to obtain an effect without neither affecting neuronal survival nor 
wasting BMSC-CM. Cells were then fixed in buffered 4% paraformaldehyde (PFA) for 10 
min. Apoptosis was evaluated with the TUNEL method, according to the manufacturer’s 
protocol (Roche). Cells were then counterstained with DAPI and mounted on glass slides. 
Photomicrographs of 20 random fields per experimental condition were taken (Olympus 
AX70) at 40x magnification.  
For each condition, the total number of apoptotic cells was reported to the total number of 
cells within the 20 fields. Experiment was repeated 3 or 4 times. The results are expressed as a 
mean apoptotic rate in percent.  
 
II.3. Ex-vivo aortic ring assay 
Rat aortic rings were cultured in three dimensional type-I collagen gels as described by 
Sounni et al. [99]. The following culture conditions were tested:  5% BMSC-CM, 5% control 
medium, 20 ng/ml rat VEGF with or without 1 µg/ml anti-rat VEGF (PeproTech). This 
proportion of BMSC-CM was chosen to limit medium dilution that could affect neovessel 
regrowth and because it already triggered a strong response. Aortic rings were cultured for 9 
days at 37°C in 5% CO2. Photomicrographs were captured, with a Zeiss phase contrast 
microscope at 2.5x magnification (Axiovert 25). A minimum of 3 aortic explants were used 
per experimental condition and experience was repeated at least 3 times. Quantification was 







II.4. Macrophage culture and activation  
Rat macrophage cell line (CRL2192) from ATCC was expanded in Ham’s F-12K 
medium (Invitrogen) supplemented with 15% heat inactivated FBS. Cells were transferred to 
Petri dishes (Falcon) at a density of 2 x 10
5
 cells/ml in the presence of Ham’s F-12K/FBS 
supplemented with: (1) 25% control medium, (2) Lipopolysaccharides (LPS) + Interferon- 
(IFN, (3) LPS + IFN + 25% BMSC-CM and (4) LPS + IFN + IL-4 + IL-13. LPS from 
Escherichia coli 0111:B4 (Sigma-Aldrich) and IFN (Millipore) were respectively used at a 
final concentration of 10 and 2 ng/ml. IL-4 and IL-13 (R&D Systems) were used at a final 
concentration of 10 ng/ml each. Proportion of 25% BMSC-CM was chosen for the same 
reason as for apoptosis experiment. After 24 h at 37°C, adherent macrophages were detached 
and cells and supernatants were collected. Cells were counted to normalize the cytokine 
concentration. Supernatants were centrifuged at 200g to eliminate cells and the cytokine 
contents were analysed by ELISA. Media without macrophages were used as controls to 
remove cytokines that could come from serum and/or BMSC-CM. Experiment was repeated 2 
to 4 times. 
 
II.5. ELISA and antibody array 
ELISA were used to assess i) the amounts of NGF, BDNF, IL-1, IL-6, TNF and IL-
10 in BMSC-CM, as well as ii) the amounts of IL-1, IL-6, TNF and IL-10 in the 
macrophage culture supernatants, according to the manufacturer’s recommendations (R&D 
Systems). For macrophage supernatant, values were related to 100,000 cells. Samples were 
run in duplicate for each experiment, and macrophage experiment was repeated 2 or 4 times. 
For BMSC-CM, samples were run in duplicate for each experiment, and experiment was 
repeated 2 to 13 times, according to the factor. Final results are expressed as a mean 
concentration in cytokine.  
In parallel, a biotin label-based rat antibody array (RayBiotech) coated with 90 antibodies was 
used to obtain a broad view of molecules present in BMSC-CM. Three conditioned media 
from passage 3 BMSC cultures were tested. 
 
II.6. Animal model 
A total of 40 adult female Wistar rats (200g) from the Animal Facility of the University of 
Liege were used. Rats were treated in strict accordance with protocols approved by the Ethical 
Commission for animal use of the University of Liege, and all efforts were made to minimize 
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suffering. Rats were housed in individual cages from 7 days before the experiment, in a 12 h 
light/dark cycle, and in a temperature-controlled environment with access to food and water 
ad libitum. Animals were randomly divided into 4 experimental groups: BMSC-CM treated 
and control animals, sacrificed 1 or 6 weeks after SCI. 10 animals were studied in each group. 
 
II.7. Contusion injury and BMSC-CM/control medium administration 
Contusion SCI was induced with the « Infinite Horizons Spinal Cord Impactor IH-
0400 » from Precision Systems and Instrumentation, LLC, Version 5.0., USA. Rats were 
deeply anaesthetized by inhalation of a mixture O2 (N25) with 5% isoflurane, anaesthesia 
being maintained with 2-3% isoflurane during surgery (Forene, Abbott).  
The skin was incised to expose the thoracic vertebral column and a T10 laminectomy was 
performed. After stabilization of the spinal column, contusion lesion was performed using a 
250 kilodynes force of impact. Dura was opened at the level of the lesion and 10 µl of BMSC-
CM or control medium were directly dropped with a Hamilton syringe onto the lesion. A 
mini-osmotic pump (model 1007D, ALZET, flow rate: 0.5 µl/ h/ 7 days) filled with BMSC-
CM or control medium and linked to a catheter was then implanted to deliver the treatment at 
the lesion site. Muscles and skin were sutured. After 1 week, rats allowed to survive for 42 
days were briefly re-anaesthetized to remove the empty pump, in order to avoid inflammation. 
Bladder function was assessed every day and manually emptied until rats regained control.  
 
II.8. Neurological function evaluation 
Two behavioural tests were used after SCI to assess motor performances of rats: the 
Basso, Beattie and Bresnahan (BBB) open-field test [101] consisting of a 21 point rating 
scale, and the grid navigation test with a 5 point scale [102]. All rats were accustomed to both 
tests 1 week before SCI. Two independent experienced individuals carried out all evaluations 
on a blind basis. 
 
II.9. Euthanasia and histological procedures 
After a deep anaesthesia with intraperitoneal injection of pentobarbital (200mg/kg, 
Nembutal, CEVA Santé Animale), rats were transcardially perfused with 300 ml cold saline 
containing 0.01% heparine (LEO Pharma), then with 500 ml cold buffered 4% PFA in 0.1M 
PBS (pH 7.4), 1 or 6 weeks post-injury. Spinal cords were dissected out, post-fixed for 24 h in 
4% PFA at 4°C and cryoprotected for 48 h in a 30% sucrose buffer at 4°C. Serial, longitudinal 
(20µm thick) and transverse (25µm) sections were performed on, respectively, 15 mm-long 
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and 10 mm-long tissue blocks centred on the lesion site. 1 out of 5 transversal sections were 
preserved. Inflammation and angiogenesis were studied on rats sacrificed 1 week after SCI 
(N=10/group), using respectively CD11b and RECA-1 (Rat Endothelial Cell Antigen) 
immunostainings, on 3 longitudinal sections/animal. Axonal regeneration, astroglial scar 
formation and cavitation were studied on rats sacrificed 6 weeks after SCI. Axonal 
regeneration and astrogliosis were evaluated by immunohistology using antibodies against 
Neurofilaments (NF) and Growth-associated protein 43 (GAP-43) for axons and Glial 
fibrillary acidic protein (GFAP) for astrocytes, on 3 longitudinal sections/animal (N=4/group). 
Finally, cystic cavity extension was measured after Luxol-fast blue/ periodic acid - Schiff / 
hematoxylin staining on 6 transverse sections/animal (N= 6/group).  
The following antibodies were used: Primary antibodies: mouse anti-NF200 (1:400, 
Sigma-Aldrich); rabbit anti-GAP-43 (1:1000, Millipore); mouse anti-GFAP (1:400, Sigma-
Aldrich), mouse anti-CD11b (1:1000, AbD Serotec); mouse anti-RECA-1 (1:200, AbCam). 
Secondary antibodies: biotinylated horse anti-mouse IgG and biotinylated goat anti-rabbit 
IgG (1:500, Vector Laboratories). For anti-NF/GAP-43/GFAP/CD11b/RECA-1, sections 
were processed as previously described [21], except fixation in acetone and incubation in 
0.5% H2O2 for RECA-1 antibody. 
 
II.10. Image analysis 
II.10.1. Cystic cavity 
To quantify cavitation along the ventro-dorsal axis, 6 stained sections/rat (N=6/group), 
covering a distance of 1500 µm on either side of the lesion epicentre, were analyzed. Each 
section was observed under microscope (Zeiss, AxioImager Z1) to measure the height of the 
ventro-dorsal extent of the cyst relative to the one of the spinal cord midline (Mercator Pro 
software, Explora Nova). The mean ratio cyst extent / spinal cord extent was calculated for 
each experimental group and expressed as percentages.      
II.10.2. Immunostaining quantification 
To quantify GFAP, NF, GAP-43 and CD11b, 3 longitudinal sections per animal were 
immunostained for each antigen. Bright field images of successive fields at 5x magnification 
were captured to perform a full reconstruction of each section (Leica DM6000B). On these 
photomicrographs, the immunostained area was measured in 3 boxed areas of 3 mm
2
 placed 
as follows: one at the lesion epicentre, one more rostrally (1000 µm from the epicentre) and 
one more caudally (1000 µm from the epicentre) (see diagram). Using analySIS software 
(Olympus), reconstructed photomicrographs were transformed in grey scales. A threshold 
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intensity of staining was applied. The immunostained surface was then measured in each of 











To quantify the blood vessel diameters, RECA-1 immunostained sections were used. 3 
longitudinal sections per animal were used and 3 fields per section were randomly chosen at 
the lesion epicentre. Bright field images at 10x magnification were captured with Zeiss 
microscope (AxioImager Z1). On each field, diameter of 10 blood vessels was measured with 
analySIS software. The blood vessel mean diameter for both experimental groups is 
considered.    
 
II.11. Statistical analysis 
All data were expressed as means ± standard error of the mean (SEM). The 
improvement of motor recovery was analyzed by Generalized Linear Mixed Model (GLMM), 
which evaluates the global evolution of the two experimental groups. Other data were 
analyzed by unpaired Student’s t-test. P-value (p) < 0.05 was considered statistically 
significant. All the tests were conducted using Statistica software (StatSoft), except for 





III.1. Characterization of rat BMSCs 
BMSCs were expanded in plastic dishes in classical in vitro conditions. Cells were 
characterized by their plastic adherence, the expression of specific antigens and their 
multipotency was checked by their differentiation capacity. Cells were used at low passages 
P2, P3 or P4, to work with young cells and avoid senescence-associated effects progressively 
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(p75NGFr) but didn't express CD45 and CD11b. Under specific induction media, cells 
differentiated into adipocytes and osteocytes (figures 1A-F).   
 
III.2. BMSC-CM protects neurons from apoptosis in vitro 
Cerebellar granule neurons (CGNs) were cultured and submitted to pro-apoptotic conditions: 
serum free medium or tumor necrosis factor alpha (TNF) (50 ng/ml). BMSC-CM was added 
in each condition at a final proportion volume of 25%. After overnight treatment, cells were 
fixed and apoptosis rates evaluated using the Tunel method and a DAPI counterstain. 
Incubation with BMSC-CM significantly decreased apoptotic rates of neurons whatever the 
experimental condition (figure 2): in serum deprivation condition, BMSC-CM decreased 
apoptotic rate by 10% (from 14.8% ± 1.1 to 4.9% ± 0.7) (p=0.0002, Student's t-test) and by 
more than 12% in TNF-induced apoptosis (from 21.2% ± 2.8 to 8.6% ± 0.6) (p=0.0038, 
Student's t-test). Results were identical with the use of BMSC-CM kept for 7 days at 37°C 
before performing the experiment (data not shown). 
 
III.3. BMSC-CM is pro-angiogenic 
As vessel growth favours axonal regrowth after SCI, we assessed the effect of BMSC-CM on 
angiogenesis. Rat aortic rings were incubated 9 days in a specific medium supplemented with 
5% BMSC-CM, 5% control medium (negative control) or recombinant rat vascular 
endothelial growth factor (VEGF, 20 ng/ml; positive control) (figure 3A). Anti-VEGF 
functional antibody (1 µg/ml) was also added to assess a possible role of VEGF in observed 
effects. The number of intersections (Ni) of neovessels as a function of the distance from the 
ring is illustrated on figure 3B. Areas below curves were calculated in order to include both 
parameters: Ni and the maximal distance from the ring reached by the neovessels. BMSC-CM 
induced a strong angiogenic response in comparison to the control (270.5 ± 18.3 vs 119.3 ± 
11) to reach approximately the same level as with VEGF treatment. Anti-VEGF 
administration abolished the pro-angiogenic effect of BMSC-CM (270.5 ± 18.3 vs 125.3 ± 
25.2) and, as expected, of VEGF. The differences were statistically significant between 
BMSC-CM and control medium (p < 0.0001, Student's t-test) and between BMSC-CM and 
BMSC-CM + anti-VEGF (p=0.0003, Student's t-test; figure 3C). This indicates that VEGF is 






III.4. BMSC-CM favours a pro-inflammatory state of macrophages in vitro  
In order to study the effects of BMSC-CM on macrophage phenotype, rat macrophages were 
activated with LPS (10ng/ml) and IFN (2 ng/ml) to simulate the in vivo inflammation that 
follows SCI. Activated macrophages were further incubated with 25% control medium, 25% 
BMSC-CM, or anti-inflammatory cytokines: interleukin 4 and 13 (IL-4 and IL-13) (10 
ng/ml). After 24h, culture media were harvested to assess their content in IL-1, IL-6, TNF 
and IL-10 by ELISA. Each value was normalized for 100,000 cells, and the concentration of 
cytokines present in BMSC-CM or serum was deduced. Without LPS/IFN stimulation, 
100,000 macrophages secreted 3.7 pg/ml ± 0.4 of IL-1, while activated cells secreted 115.5 
pg/ml ± 31.2. Incubation with BMSC-CM significantly increased IL-1 concentration in 
supernatant of activated macrophages from 115.5 pg/ml ± 31.2 to 206 pg/ml ± 19 (p=0.048, 
Student's t-test). The use of IL-4 and IL-13 on activated macrophages reduced slightly the 
secretion of IL-1 to 95.6 pg/ml ± 10.2 (figure 4A). IL-6 and TNF values also show a 
tendency to increase after BMSC-CM treatment, without reaching significant levels of 
differences (figures 4B-C). On the contrary, no secretion of IL-10 was observed (data not 
shown). Thus, BMSC-CM is globally pro-inflammatory on macrophages, as it exacerbates 
their secretion of pro-inflammatory cytokines.  
 
III.5. BMSC-CM characterization   
In order to further characterize BMSC-CM, we performed large antibody arrays (90 proteins) 
as well as ELISA assays. Antibody arrays, performed on 3 distinct BMSC-CM samples 
(figure 5A), reveal the presence of 23 factors involved in either apoptosis, inflammation, 
angiogenesis, oxidative stress, excitotoxicity, all involved in the modulation of the spinal cord 
injured environment  (Table 1).    
ELISA were performed on 4 cytokines: IL-6, IL-1, TNF, IL-10 and 2 neurotrophins: brain-
derived neurotrophic factor (BDNF), nerve growth factor (NGF). The analysis of different 
BMSC-CM demonstrates that NGF and BDNF are present at 356 pg/ml ± 117 and 208 pg/ml 
± 57 respectively, as well as IL-6 at 427 pg/ml ± 168 (figure 5B). IL-1, TNF and IL-10 
were not detected in these samples. 
 
III.6. BMSC-CM improves functional recovery after SCI 
Spinal cord injured animals were submitted to 2 complementary behavioural tests. The Basso, 
Beattie and Bresnahan (BBB) open-field test was used to assess motor skills of rats until 6 
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weeks post-injury (figure 6A). The difference between treated and control groups was 
statistically significant (Injured + BMSC-CM vs Injured + control p=0.0003, Generalized 
Linear Mixed Model). From day 4 after SCI, BMSC-CM treated animals show better scores 
than control animals and this difference was maintained during the study. Score 9 is crucial as 
it indicates the weight support step. The figure shows that this stage is reached by treated 
animals 4 days before control animals. Moreover, control animals never recovered their 
ability to separate toes and to maintain hindpaws in a parallel position at lift off during 
stepping (score of 16). These parameters, successfully performed by treated animals, bear 
witness to a fine recovery of motricity.  
The grid navigation test was used to assess fine motor coordination and movement accuracy 
(figure 6B). Mean scores over time were significantly higher in BMSC-CM treated group 
compared to control group (Injured + BMSC-CM  vs Injured + control p=0.0001, 
Generalized Linear Mixed Model). We noticed that difference between both groups started 
from day 4 post-injury. Score 4, testifying a correct placement on grid bars, was reached only 
by BMSC-CM treated animals.  
 
III.7. BMSC-CM reduces cystic cavity 
The improved motor recovery observed in BMSC-CM treated animals could be explained by 
a reduced extension of the lesion. To investigate this aspect, spinal cord injured transversal 
sections from both experimental groups were performed 6 weeks after injury and stained with 
Luxol-fast-blue / periodic acid - Schiff / hematoxylin. Serial sections were then analyzed to 
quantify the ventro-dorsal extent of the cystic cavity (figures 7A-B).  As spinal cord volume 
can vary over the lesion epicentre, cystic height was related to spinal cord height on the same 
dorso-ventral axis, and ratio expressed in percentages. BMSC-CM treated group shows 
reduced mean values compared to control group (Injured + BMSC-CM: 67.72% ± 3.4 vs 
Injured + control: 83.4% ± 2.1; figure 7C). Difference between BMSC-CM treated and 
control groups was statistically significant (p=0.0029, Student's t-test).    
 
III.8. BMSC-CM is pro-angiogenic in vivo 
Longitudinal spinal cord injured sections from treated and control groups were performed 1 
week post-injury and immunostained for RECA-1. Diameters of blood vessels were measured 
at the lesion epicentre. Blood vessels exhibit larger diameters in BMSC-CM treated animals 
compared to controls (Injured + BMSC-CM: 14.4 µm ± 1.2 vs Injured + control: 6.9 µm ± 
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0.8; figures 8A-B). Difference between both groups was statistically significant (p<0.0001, 
Student's t-test) .  
 
III.9. In vivo, BMSC-CM has no effect on astrogliosis, macrophage invasion and axonal 
regrowth 
To study astrogliosis, longitudinal sections performed 6 weeks after injury were 
immunostained for GFAP. Quantification of the immunostained surface was carried out in 3 
defined areas. This value was related to the total area of each of the 3 zones to express a 
proportion of stained area. We didn't detect any difference between BMSC-CM treated and 
control animals (Student's t-test). After CD11b immunostaining, quantifications were 
performed as described above. Values obtained for BMSC-CM treated and control groups 
were not significantly different (Student's t-test). In order to assess the ability of BMSC-CM 
to favour axonal regrowth after SCI, anti-NF and anti-GAP-43 immunostainings were 
performed. Quantifications didn't reveal any difference between groups, whatever the delay 





Our results show that, in vitro, BMSC-CM provides protection against neuronal apoptosis, is 
pro-angiogenic and confers a pro-inflammatory phenotype to macrophages. In vivo, we 
demonstrate for the first time that BMSC-released molecules are able to reduce cystic cavity 
size along the ventro-dorsal axis at the lesion epicentre, to favour large blood vessel growth 
and to improve locomotor recovery in a spinal cord contusion injury model.  
Many studies suggest that beneficial effects obtained after BMSC transplantation in SCI were 
more likely due to paracrine actions than to effective integration and differentiation of the 
cells within the host tissue [21,23,36,38,50-53]. Our study confirms this hypothesis.  
We decided to deliver factors secreted by BMSCs in the form of concentrated conditioned 
medium (CM), to optimize potential effects. We also chose to use a fraction of this BMSC-
CM that contains factors of a molecular weight > 10 kDa, as this fraction was earlier 
described as beneficial on myocardial infarct size, oxidative stress and apoptosis [54]. 
Moreover, we eliminated serum from the medium because of its poorly defined composition.  
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Two complementary behavioural tests were used to assess recovery of motor functions: BBB 
as a global recovery test, and grid navigation to evaluate more precisely fine motor 
movements. In both tests, control animals show spontaneous recovery after spinal cord 
contusion. The great spontaneous recovery obtained here can also be explained by the type of 
the lesion, which, despite the use of a 250 kdyn force, doesn't severely affect the ventral part 
of the spinal cord, thus preserving white matter tracts [55]. According to the literature, 200 
kdyn already corresponds to a severe injury, but this parameter is also known to vary upon the 
animal weight or strain [56,57]. Despite this fact, BMSC-CM treated rats obtained 
significantly higher scores in both tests compared to control animals. Difference between 
groups started from days 4 to 7, indicating a rapid effect after administration, as also 
described after BMSC transplantation in a model of spinal cord contusion injury [24]. Later 
on, BBB scores continue to improve, with treated rats displaying at each delay higher scores 
compared to controls. In their study, Namiki et al. showed an improvement of inclined plane 
scores one week after BDNF infusion by osmotic pump in a SCI clip model. However, this 
evolution stopped very early after the end of the BDNF treatment [58]. The prolonged effect 
that we obtain may be due to the combined action of several factors present in our CM, with 
maybe redundant molecules with variable bioavailabilities. It is also possible that the cocktail 
of administered factors favours the survival of endogenous cells preserving the tissue from 
further lesion extension.  
In other studies, after BMSC transplantation in contusion or compression models of rat SCI, 
locomotor improvements were also observed during weeks following the graft, with BBB 
scores reaching similar levels. For example, 4 weeks after spinal contusion and BMSC graft, 
Karaoz and colleagues obtain a BBB score of 15 while our treated rats reach the score of 16 at 
the same delay. Also, 3 weeks after BMSC graft in a compression injury model, Quertainmont 
et al. show that rats reach a BBB score of 12 which is even lower to the score of 15 reached in 
the present study [21,24]. This reinforces our hypothesis that BMSC-secreted factors are 
beneficial after SCI and that they improve functional recovery as do BMSC transplants.  
Improved recovery can be a consequence of neural tissue protection, which is favoured by 
angiogenesis. Angiogenesis is indeed known to induce axonal regrowth via the supply of 
oxygen and nutritional factors that helps preserving injured spinal tissue from further 
degradation [59,60]. Moreover, it has been shown that the pro-angiogenic VEGF molecule 
possesses neuroprotective properties [61-63]. This factor is present in BMSC-CM and our in 
vitro data on aortic rings confirm that it is involved in the pro-angiogenic effect. Other factors 
which are known to promote angiogenesis were also detected in BMSC-CM: osteopontin 
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[64,65], matrix metalloproteinase-13 (MMP-13) [66] and fibroblast growth factor-binding 
protein (FGF-BP) [67,68]. In vivo, blood vessels observed at the lesion epicentre of treated 
animals, even if not higher in number, have larger diameters compared to controls, and could 
thus provide, via increased blood flow, more nutritional substances and oxygen to damaged 
tissue, contributing to tissue protection, as already described after thoraco-abdominal 
aneurysm in pigs [69]. Lu et al. have also measured this parameter and their data suggest that 
atorvastatin treatment elicits larger vascular diameter, thus contributing to enhanced regional 
blood flow perfusion and neuron rescue [70]. So, larger diameters of blood vessels seem to be 
associated with a better tissue perfusion, protecting neuronal cells from degeneration. Yet, we 
didn't observe increased axon regeneration in treated spinal cords compared to control ones. 
In the same context, Dray’s study suggests that even if some axons benefit from vascular 
support to accelerate their growth, this support is only transient and limited in time [60].  
Tissue protection could also be related to a reduced apoptosis rate within the injured cord. Our 
data show that BMSC-CM protects neurons from apoptosis in vitro. Neuronal death and 
apoptosis rapidly followed by oligodendrocyte apoptosis are parts of secondary processes 
making the lesion worse. BMSC transplantations have been successfully used to reduce 
apoptotic death in the context of SCI, and associated to a better motor recovery [32]. In this 
study, we demonstrate that BMSC-CM treated spinal cords have a reduced depth of cystic 
cavity, protecting white matter tracts. You et al. demonstrated a positive correlation between 
spared ventral white matter and the final BBB scores of rats [55]. Also, the rubrospinal tract 
in the dorsolateral part and the corticospinal tract located in the dorsal part of the spinal cord 
white matter in rats are particularly important for precise limb movements, and can be 
assessed by grid navigation test [71]. Based on our behavioural data, we can thus conclude 
that the better motor recovery observed in BMSC-CM treated animals is a direct consequence 
of improved tissue sparing.  
Among factors identified in BMSC-CM by cytokine arrays and ELISA, some may also 
contribute to tissue preservation. NGF stimulates the survival of sympathetic and sensory 
neurons, while TIMP-1 (tissue inhibitor of metalloproteinase-1) and CINC-3 (cytokine-
induced neutrophil chemoattractant-3) are neuroprotective [72,73]. BDNF administration 
decreases apoptosis and demyelination in a spinal cord compression model [74] and reduces 
astroglial scar formation [75]. Also, other factors, thus not described here, are known to be 
secreted by rat BMSCs: IGF-1, HGF, TGF-β1, EGF, SDF-1, MIP-1α/β, GM-CSF or FGF-2 
[76,77]. The fact that we didn't find those factors is first due to the fact that some of them 
were not included in our 90-protein array assay. Moreover, BMSC culture conditions may 
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influence their secretome, which would explain why factors described in other studies were 
not detected here and conversely.  
In our model, BMSC-CM doesn’t affect astroglial reactivity. This result could be considered 
as unexpected, as both NGF and BDNF, present in BMSC-CM, are known to reduce reactive 
astrogliosis [75,78]. This discrepancy is likely due to the variable concentrations of these two 
neurotrophins. Also, according to the literature, few studies report any effect of BMSC 
transplantation on astroglial scar development after SCI. This is also the case for axonal 
regeneration, which is rarely reported as associated to improved recovery after BMSC 
transplants [24,79-82]. 
In vitro data on IFN/LPS-activated macrophages show that BMSC-CM further favours their 
pro-inflammatory state, as assessed by their significant increased IL-1 secretion and their 
obvious but non-significant increased IL-6 and TNF production. In parallel, we also show 
that BMSC-CM contains IL-6, which possesses pro-inflammatory properties as well [83,84]. 
In vivo, we didn’t detect any difference between treated and control groups, in the number of 
macrophages that invaded the lesion site 1 week post-injury, as assessed by the total area 
stained for CD11b. Microglia/macrophages present within the lesion exhibited in both groups 
round cell bodies without branching processes, characteristic of "amoeboid" cells, and 
indicative of an activated status. This reactive cell form is associated with neuroprotective 
effects via trophic factor delivery and with phagocytosis that is essential to remove cell and 
myelin debris [23,85-87]. In this context, we hypothesize that BMSC-CM has further 
favoured the activated state of resident microglia and invading macrophages, conferring a 
phenotype beneficial for tissue preservation, without affecting the number of inflammatory 
cells within the lesion. This hypothesis is in accordance with the fact that IL-1 and IL-6 do 
indirectly promote axonal outgrowth [88,89] and protect neurons from death [90,91]. In the 
literature, contradictory results have been described concerning the effect of BMSC 
transplantation on post-injury inflammatory reaction, going from reduced inflammation [92] 
to enhanced macrophage/microglia response [81]. Some authors also suggest that microglial 
activation after SCI is linked to the reduction of the lesion size [23,93]. Indeed, microglia can 
be involved in neuroprotection via secretion of factors such as NGF, IGF-1 (insulin-like 
growth factor-1) or via up-regulation of FGF-2 (fibroblast growth factor-2) in neurons [94-
96]. 
In conclusion, our data show that the use of BMSC-CM in the context of SCI is beneficial and 
not deleterious, and leads to improved motor recovery. This treatment constitutes a novel 
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promising therapeutic perspective in SCI context. More investigations are needed to evaluate 




The authors are grateful to Ms Pieltain, Mr. Roland, Ms. Mosen, Ms. Ernst, Ms. Wouters 
for their technical assistance to this work, and to Ms. Seidel for all statistical analysis. We 




1. Popovich PG, Wei P, Stokes BT (1997) Cellular inflammatory response after spinal cord 
injury in Sprague-Dawley and Lewis rats. J Comp Neurol 377: 443-464. 
2. Hausmann ON (2003) Post-traumatic inflammation following spinal cord injury. Spinal 
Cord 41: 369-378. 
3. Hall ED (2011) Antioxidant Therapies for Acute Spinal Cord Injury. Neurotherapeutics 8: 
152-167. 
4. Park E, Velumian AA, Fehlings MG (2004) The role of excitotoxicity in secondary 
mechanisms of spinal cord injury: a review with an emphasis on the implications for 
white matter degeneration. J Neurotrauma 21: 754-774. 
5. Warden P, Bamber NI, Li H, Esposito A, Ahmad KA, et al. (2001) Delayed glial cell death 
following wallerian degeneration in white matter tracts after spinal cord dorsal column 
cordotomy in adult rats. Exp Neurol 168: 213-224. 
6. Guest JD, Hiester ED, Bunge RP (2005) Demyelination and Schwann cell responses 
adjacent to injury epicenter cavities following chronic human spinal cord injury. Exp 
Neurol 192: 384-393. 
7. Kato H, Kanellopoulos GK, Matsuo S, Wu YJ, Jacquin MF, et al. (1997) Neuronal 
apoptosis and necrosis following spinal cord ischemia in the rat. Exp Neurol 148: 464-
474. 
8. Fujiki M, Kobayashi H, Inoue R, Goda M (2004) Electrical preconditioning attenuates 
progressive necrosis and cavitation following spinal cord injury. J Neurotrauma 21: 
459-470. 
9. Wagner FC, Jr., Van Gilder JC, Dohrmann GJ (1977) The development of intramedullary 
cavitation following spinal cord injury: an experimental pathological study. Paraplegia 
14: 245-250. 
10. Wozniewicz B, Filipowicz K, Swiderska SK, Deraka K (1983) Pathophysiological 
mechanism of traumatic cavitation of the spinal cord. Paraplegia 21: 312-317. 
11. Nishio T (2009) Axonal regeneration and neural network reconstruction in mammalian 
CNS. J Neurol 256 Suppl 3: 306-309. 
12. Beattie MS (2004) Inflammation and apoptosis: linked therapeutic targets in spinal cord 
injury. Trends Mol Med 10: 580-583. 
13. Oatway MA, Chen Y, Bruce JC, Dekaban GA, Weaver LC (2005) Anti-CD11d integrin 
antibody treatment restores normal serotonergic projections to the dorsal, intermediate, 
and ventral horns of the injured spinal cord. J Neurosci 25: 637-647. 
18 
 
14. Genovese T, Mazzon E, Muia C, Bramanti P, De Sarro A, et al. (2005) Attenuation in the 
evolution of experimental spinal cord trauma by treatment with melatonin. J Pineal 
Res 38: 198-208. 
15. Song Y, Zeng Z, Jin C, Zhang J, Ding B, et al. (2012) Protective Effect of Ginkgolide B 
Against Acute Spinal Cord Injury in Rats and Its Correlation with the JAK/STAT 
Signaling Pathway. Neurochem Res. 
16. van den Brand R, Heutschi J, Barraud Q, DiGiovanna J, Bartholdi K, et al. (2012) 
Restoring voluntary control of locomotion after paralyzing spinal cord injury. Science 
336: 1182-1185. 
17. Fan C, Zheng Y, Cheng X, Qi X, Bu P, et al. (2013) Transplantation of D15A-Expressing 
Glial-Restricted-Precursor-Derived Astrocytes Improves Anatomical and Locomotor 
Recovery after Spinal Cord Injury. Int J Biol Sci 9: 78-93. 
18. Liu J, Chen J, Liu B, Yang C, Xie D, et al. (2013) Acellular spinal cord scaffold seeded 
with mesenchymal stem cells promotes long-distance axon regeneration and functional 
recovery in spinal cord injured rats. J Neurol Sci. 
19. Dasari VR, Spomar DG, Gondi CS, Sloffer CA, Saving KL, et al. (2007) Axonal 
remyelination by cord blood stem cells after spinal cord injury. J Neurotrauma 24: 
391-410. 
20. Li X, Liu X, Cui L, Brunson C, Zhao W, et al. (2012) Engineering an in situ crosslinkable 
hydrogel for enhanced remyelination. FASEB J. 
21. Quertainmont R, Cantinieaux D, Botman O, Sid S, Schoenen J, et al. (2012) Mesenchymal 
Stem Cell Graft Improves Recovery after Spinal Cord Injury in Adult Rats through 
Neurotrophic and Pro-Angiogenic Actions. PLoS One 7: e39500. 
22. Choi JS, Leem JW, Lee KH, Kim SS, Suh-Kim H, et al. (2012) Effects of human 
mesenchymal stem cell transplantation combined with polymer on functional recovery 
following spinal cord hemisection in rats. Korean J Physiol Pharmacol 16: 405-411. 
23. Boido M, Garbossa D, Fontanella M, Ducati A, Vercelli A (2012) Mesenchymal Stem 
Cell Transplantation Reduces Glial Cyst and Improves Functional Outcome After 
Spinal Cord Compression. World Neurosurg. 
24. Karaoz E, Kabatas S, Duruksu G, Okcu A, Subasi C, et al. (2012) Reduction of lesion in 
injured rat spinal cord and partial functional recovery of motility after bone marrow 
derived mesenchymal stem cell transplantation. Turk Neurosurg 22: 207-217. 
25. Tharion G, Indirani K, Durai M, Meenakshi M, Devasahayam SR, et al. (2011) Motor 
recovery following olfactory ensheathing cell transplantation in rats with spinal cord 
injury. Neurol India 59: 566-572. 
26. Franzen R, Schoenen J, Leprince P, Joosten E, Moonen G, et al. (1998) Effects of 
macrophage transplantation in the injured adult rat spinal cord: a combined 
immunocytochemical and biochemical study. J Neurosci Res 51: 316-327. 
27. Assina R, Sankar T, Theodore N, Javedan SP, Gibson AR, et al. (2008) Activated 
autologous macrophage implantation in a large-animal model of spinal cord injury. 
Neurosurg Focus 25: E3. 
28. Oudega M, Xu XM (2006) Schwann cell transplantation for repair of the adult spinal cord. 
J Neurotrauma 23: 453-467. 
29. Cusimano M, Biziato D, Brambilla E, Donega M, Alfaro-Cervello C, et al. (2012) 
Transplanted neural stem/precursor cells instruct phagocytes and reduce secondary 
tissue damage in the injured spinal cord. Brain 135: 447-460. 
30. Nakajima H, Uchida K, Guerrero AR, Watanabe S, Sugita D, et al. (2012) Transplantation 
of mesenchymal stem cells promotes an alternative pathway of macrophage activation 
and functional recovery after spinal cord injury. J Neurotrauma 29: 1614-1625. 
19 
 
31. Uccelli A, Benvenuto F, Laroni A, Giunti D (2011) Neuroprotective features of 
mesenchymal stem cells. Best Pract Res Clin Haematol 24: 59-64. 
32. Dasari VR, Spomar DG, Cady C, Gujrati M, Rao JS, et al. (2007) Mesenchymal stem cells 
from rat bone marrow downregulate caspase-3-mediated apoptotic pathway after 
spinal cord injury in rats. Neurochem Res 32: 2080-2093. 
33. Osaka M, Honmou O, Murakami T, Nonaka T, Houkin K, et al. (2010) Intravenous 
administration of mesenchymal stem cells derived from bone marrow after contusive 
spinal cord injury improves functional outcome. Brain Res 1343: 226-235. 
34. Ide C, Nakai Y, Nakano N, Seo TB, Yamada Y, et al. (2010) Bone marrow stromal cell 
transplantation for treatment of sub-acute spinal cord injury in the rat. Brain Res 1332: 
32-47. 
35. Wu S, Suzuki Y, Ejiri Y, Noda T, Bai H, et al. (2003) Bone marrow stromal cells enhance 
differentiation of cocultured neurosphere cells and promote regeneration of injured 
spinal cord. J Neurosci Res 72: 343-351. 
36. Himes BT, Neuhuber B, Coleman C, Kushner R, Swanger SA, et al. (2006) Recovery of 
function following grafting of human bone marrow-derived stromal cells into the 
injured spinal cord. Neurorehabil Neural Repair 20: 278-296. 
37. Rooney GE, McMahon SS, Ritter T, Garcia Y, Moran C, et al. (2009) Neurotrophic 
factor-expressing mesenchymal stem cells survive transplantation into the contused 
spinal cord without differentiating into neural cells. Tissue Eng Part A 15: 3049-3059. 
38. Cizkova D, Rosocha J, Vanicky I, Jergova S, Cizek M (2006) Transplants of human 
mesenchymal stem cells improve functional recovery after spinal cord injury in the rat. 
Cell Mol Neurobiol 26: 1167-1180. 
39. Wong RS (2011) Mesenchymal stem cells: angels or demons? J Biomed Biotechnol 2011: 
459510. 
40. Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, et al. (2007) Potential risks of bone 
marrow cell transplantation into infarcted hearts. Blood 110: 1362-1369. 
41. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, et al. (2006) Accumulated 
chromosomal instability in murine bone marrow mesenchymal stem cells leads to 
malignant transformation. Stem Cells 24: 1095-1103. 
42. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem 
cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563. 
43. Kunter U, Rong S, Boor P, Eitner F, Muller-Newen G, et al. (2007) Mesenchymal stem 
cells prevent progressive experimental renal failure but maldifferentiate into 
glomerular adipocytes. J Am Soc Nephrol 18: 1754-1764. 
44. Jeong JO, Han JW, Kim JM, Cho HJ, Park C, et al. (2011) Malignant tumor formation 
after transplantation of short-term cultured bone marrow mesenchymal stem cells in 
experimental myocardial infarction and diabetic neuropathy. Circ Res 108: 1340-1347. 
45. Timmers L, Lim SK, Hoefer IE, Arslan F, Lai RC, et al. (2011) Human mesenchymal 
stem cell-conditioned medium improves cardiac function following myocardial 
infarction. Stem Cell Res 6: 206-214. 
46. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, et al. (2004) Local delivery of 
marrow-derived stromal cells augments collateral perfusion through paracrine 
mechanisms. Circulation 109: 1543-1549. 
47. Togel F, Weiss K, Yang Y, Hu Z, Zhang P, et al. (2007) Vasculotropic, paracrine actions 
of infused mesenchymal stem cells are important to the recovery from acute kidney 
injury. Am J Physiol Renal Physiol 292: F1626-1635. 
48. Kim HJ, Lee JH, Kim SH (2010) Therapeutic effects of human mesenchymal stem cells 
on traumatic brain injury in rats: secretion of neurotrophic factors and inhibition of 
apoptosis. J Neurotrauma 27: 131-138. 
20 
 
49. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, et al. (2008) Replicative 
senescence of mesenchymal stem cells: a continuous and organized process. PLoS 
One 3: e2213. 
50. Urdzikova L, Jendelova P, Glogarova K, Burian M, Hajek M, et al. (2006) 
Transplantation of bone marrow stem cells as well as mobilization by granulocyte-
colony stimulating factor promotes recovery after spinal cord injury in rats. J 
Neurotrauma 23: 1379-1391. 
51. Chopp M, Zhang XH, Li Y, Wang L, Chen J, et al. (2000) Spinal cord injury in rat: 
treatment with bone marrow stromal cell transplantation. Neuroreport 11: 3001-3005. 
52. Vaquero J, Zurita M, Oya S, Santos M (2006) Cell therapy using bone marrow stromal 
cells in chronic paraplegic rats: systemic or local administration? Neurosci Lett 398: 
129-134. 
53. Park SI, Lim JY, Jeong CH, Kim SM, Jun JA, et al. (2012) Human umbilical cord blood-
derived mesenchymal stem cell therapy promotes functional recovery of contused rat 
spinal cord through enhancement of endogenous cell proliferation and oligogenesis. J 
Biomed Biotechnol 2012: 362473. 
54. Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, et al. (2007) Reduction of 
myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem 
Cell Res 1: 129-137. 
55. You SW, Chen BY, Liu HL, Lang B, Xia JL, et al. (2003) Spontaneous recovery of 
locomotion induced by remaining fibers after spinal cord transection in adult rats. 
Restor Neurol Neurosci 21: 39-45. 
56. Scheff SW, Rabchevsky AG, Fugaccia I, Main JA, Lumpp JE, Jr. (2003) Experimental 
modeling of spinal cord injury: characterization of a force-defined injury device. J 
Neurotrauma 20: 179-193. 
57. Simon CM, Sharif S, Tan RP, LaPlaca MC (2009) Spinal cord contusion causes acute 
plasma membrane damage. J Neurotrauma 26: 563-574. 
58. Namiki J, Kojima A, Tator CH (2000) Effect of brain-derived neurotrophic factor, nerve 
growth factor, and neurotrophin-3 on functional recovery and regeneration after spinal 
cord injury in adult rats. J Neurotrauma 17: 1219-1231. 
59. Hobson MI, Green CJ, Terenghi G (2000) VEGF enhances intraneural angiogenesis and 
improves nerve regeneration after axotomy. J Anat 197 Pt 4: 591-605. 
60. Dray C, Rougon G, Debarbieux F (2009) Quantitative analysis by in vivo imaging of the 
dynamics of vascular and axonal networks in injured mouse spinal cord. Proc Natl 
Acad Sci U S A 106: 9459-9464. 
61. Sun Y, Jin K, Xie L, Childs J, Mao XO, et al. (2003) VEGF-induced neuroprotection, 
neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111: 1843-
1851. 
62. Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: once regarded as a specific 
angiogenic factor, now implicated in neuroprotection. Bioessays 26: 943-954. 
63. Sundberg LM, Herrera JJ, Narayana PA (2011) Effect of vascular endothelial growth 
factor treatment in experimental traumatic spinal cord injury: in vivo longitudinal 
assessment. J Neurotrauma 28: 565-578. 
64. Wang Y, Yan W, Lu X, Qian C, Zhang J, et al. (2011) Overexpression of osteopontin 
induces angiogenesis of endothelial progenitor cells via the 
avbeta3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 90: 
642-648. 
65. Dai J, Peng L, Fan K, Wang H, Wei R, et al. (2009) Osteopontin induces angiogenesis 




66. Lederle W, Hartenstein B, Meides A, Kunzelmann H, Werb Z, et al. (2010) MMP13 as a 
stromal mediator in controlling persistent angiogenesis in skin carcinoma. 
Carcinogenesis 31: 1175-1184. 
67. Li WM, Chen WB (2004) Effect of FGF-BP on angiogenesis in squamous cell carcinoma. 
Chin Med J (Engl) 117: 621-623. 
68. Harris VK, Coticchia CM, Kagan BL, Ahmad S, Wellstein A, et al. (2000) Induction of 
the angiogenic modulator fibroblast growth factor-binding protein by epidermal 
growth factor is mediated through both MEK/ERK and p38 signal transduction 
pathways. J Biol Chem 275: 10802-10811. 
69. Geisbusch S, Schray D, Bischoff MS, Lin HM, Griepp RB, et al. (2012) Imaging of 
vascular remodeling after simulated thoracoabdominal aneurysm repair. J Thorac 
Cardiovasc Surg 144: 1471-1478. 
70. Lu D, Mahmood A, Goussev A, Schallert T, Qu C, et al. (2004) Atorvastatin reduction of 
intravascular thrombosis, increase in cerebral microvascular patency and integrity, and 
enhancement of spatial learning in rats subjected to traumatic brain injury. J 
Neurosurg 101: 813-821. 
71. Schucht P, Raineteau O, Schwab ME, Fouad K (2002) Anatomical correlates of locomotor 
recovery following dorsal and ventral lesions of the rat spinal cord. Exp Neurol 176: 
143-153. 
72. Tejima E, Guo S, Murata Y, Arai K, Lok J, et al. (2009) Neuroprotective effects of 
overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma 26: 1935-
1941. 
73. Wang Y, Luo W, Reiser G (2007) Activation of protease-activated receptors in astrocytes 
evokes a novel neuroprotective pathway through release of chemokines of the growth-
regulated oncogene/cytokine-induced neutrophil chemoattractant family. Eur J 
Neurosci 26: 3159-3168. 
74. Uchida K, Nakajima H, Hirai T, Yayama T, Chen K, et al. (2012) The retrograde delivery 
of adenovirus vector carrying the gene for brain-derived neurotrophic factor protects 
neurons and oligodendrocytes from apoptosis in the chronically compressed spinal 
cord of twy/twy mice. Spine (Phila Pa 1976) 37: 2125-2135. 
75. Jain A, McKeon RJ, Brady-Kalnay SM, Bellamkonda RV (2011) Sustained delivery of 
activated Rho GTPases and BDNF promotes axon growth in CSPG-rich regions 
following spinal cord injury. PLoS One 6: e16135. 
76. Nakano N, Nakai Y, Seo T-B, Yamada Y, Ohno T, et al. (2010) Characterization of 
conditioned medium of cultured bone marrow stromal cells. Neurosci Lett 483(1): 57-
61. 
77. Hoch AI, Binder BY, Genetos DC, Leach JK (2012) Differentiation-dependent secretion 
 of proangiogenic factors by mesenchymal stem cells. PLoS One 7(4): e35579. 
78. Cirillo G, Bianco MR, Colangelo AM, Cavaliere C, Daniele de L, et al. (2011) Reactive 
astrocytosis-induced perturbation of synaptic homeostasis is restored by nerve growth 
factor. Neurobiol Dis 41: 630-639. 
79. Paul C, Samdani AF, Betz RR, Fischer I, Neuhuber B (2009) Grafting of human bone 
marrow stromal cells into spinal cord injury: a comparison of delivery methods. Spine 
(Phila Pa 1976) 34: 328-334. 
80. Nandoe Tewarie RD, Hurtado A, Ritfeld GJ, Rahiem ST, Wendell DF, et al. (2009) Bone 
marrow stromal cells elicit tissue sparing after acute but not delayed transplantation 
into the contused adult rat thoracic spinal cord. J Neurotrauma 26: 2313-2322. 
81. Samdani AF, Paul C, Betz RR, Fischer I, Neuhuber B (2009) Transplantation of human 
marrow stromal cells and mono-nuclear bone marrow cells into the injured spinal 
cord: a comparative study. Spine (Phila Pa 1976) 34: 2605-2612. 
22 
 
82. Kang ES, Ha KY, Kim YH (2012) Fate of transplanted bone marrow derived 
mesenchymal stem cells following spinal cord injury in rats by transplantation routes. 
J Korean Med Sci 27: 586-593. 
83. Gabay C (2006) Interleukin-6 and chronic inflammation. Arthritis Res Ther 8 Suppl 2: S3. 
84. Pedroza M, Schneider DJ, Karmouty-Quintana H, Coote J, Shaw S, et al. (2011) 
Interleukin-6 contributes to inflammation and remodeling in a model of adenosine 
mediated lung injury. PLoS One 6: e22667. 
85. Neumann J, Gunzer M, Gutzeit HO, Ullrich O, Reymann KG, et al. (2006) Microglia 
provide neuroprotection after ischemia. FASEB J 20: 714-716. 
86. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, et al. (1998) Fibrillar beta-
amyloid induces microglial phagocytosis, expression of inducible nitric oxide 
synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 
18: 2161-2173. 
87. Fuller AD, Van Eldik LJ (2008) MFG-E8 regulates microglial phagocytosis of apoptotic 
neurons. J Neuroimmune Pharmacol 3: 246-256. 
88. Yang P, Wen H, Ou S, Cui J, Fan D (2012) IL-6 promotes regeneration and functional 
recovery after cortical spinal tract injury by reactivating intrinsic growth program of 
neurons and enhancing synapse formation. Exp Neurol 236: 19-27. 
89. Parish CL, Finkelstein DI, Tripanichkul W, Satoskar AR, Drago J, et al. (2002) The role 
of interleukin-1, interleukin-6, and glia in inducing growth of neuronal terminal arbors 
in mice. J Neurosci 22: 8034-8041. 
90. Liu Z, Qiu YH, Li B, Ma SH, Peng YP (2011) Neuroprotection of interleukin-6 against 
NMDA-induced apoptosis and its signal-transduction mechanisms. Neurotox Res 19: 
484-495. 
91. Li XZ, Bai LM, Yang YP, Luo WF, Hu WD, et al. (2009) Effects of IL-6 secreted from 
astrocytes on the survival of dopaminergic neurons in lipopolysaccharide-induced 
inflammation. Neurosci Res 65: 252-258. 
92. Zeng X, Zeng YS, Ma YH, Lu LY, Du BL, et al. (2011) Bone marrow mesenchymal stem 
cells in a three-dimensional gelatin sponge scaffold attenuate inflammation, promote 
angiogenesis, and reduce cavity formation in experimental spinal cord injury. Cell 
Transplant 20: 1881-1899. 
93. Keimpema E, Fokkens MR, Nagy Z, Agoston V, Luiten PG, et al. (2009) Early transient 
presence of implanted bone marrow stem cells reduces lesion size after cerebral 
ischaemia in adult rats. Neuropathol Appl Neurobiol 35: 89-102. 
94. Figueiredo C, Pais TF, Gomes JR, Chatterjee S (2008) Neuron-microglia crosstalk up-
regulates neuronal FGF-2 expression which mediates neuroprotection against 
excitotoxicity via JNK1/2. J Neurochem 107: 73-85. 
95. Bruce-Keller AJ (1999) Microglial-neuronal interactions in synaptic damage and 
recovery. J Neurosci Res 58: 191-201. 
96. Lalancette-Hebert M, Gowing G, Simard A, Weng YC, Kriz J (2007) Selective ablation of 
proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci 27: 
2596-2605. 
97. Wislet-Gendebien S, Leprince P, Moonen G, Rogister B (2003) Regulation of neural 
markers nestin and GFAP expression by cultivated bone marrow stromal cells. J Cell 
Sci 116: 3295-3302. 
98. Hans G, Malgrange B, Lallemend F, Crommen J, Wislet-Gendebien S, et al. (2005) Beta-
carbolines induce apoptosis in cultured cerebellar granule neurons via the 
mitochondrial pathway. Neuropharmacology 48: 105-117. 
23 
 
99. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, et al. (2002) MT1-MMP 
expression promotes tumor growth and angiogenesis through an up-regulation of 
vascular endothelial growth factor expression. FASEB J 16: 555-564. 
100. Blacher S, Devy L, Burbridge MF, Roland G, Tucker G, et al. (2001) Improved 
quantification of angiogenesis in the rat aortic ring assay. Angiogenesis 4: 133-142. 
101. Basso DM, Beattie MS, Bresnahan JC (1995) A sensitive and reliable locomotor rating 
scale for open field testing in rats. J Neurotrauma 12: 1-21. 
102. Perrin FE, Boniface G, Serguera C, Lonjon N, Serre A, et al. (2010) Grafted human 
embryonic progenitors expressing neurogenin-2 stimulate axonal sprouting and 






Figure 1. BMSC characterization. P4 BMSCs in vitro are immunostained for (A) CD90 and 
(B) CD271 (p75NGFr), but are negative for (C) CD45 and (D) CD11b. Nuclei are labelled 
with Vectashield-DAPI mounting medium. (E) Adipogenic differentiation of P4 BMSC 
revealed with Oil Red O and (F) osteocyte differentiation revealed by Alizarin Red S.  
 
Figure 2. BMSC-CM protects neurons from apoptosis.  
Percentage of apoptotic CGN in serum-free medium or with TNF (50 ng/ml), cultured with 
or without 25% BMSC-CM. BMSC-CM significantly decreases apoptosis. Experiment was 
repeated 3 to 4 times. *** p <0.001; ** p <0.01. 
 
Figure 3. BMSC-CM promotes angiogenesis in vitro.  
(A) Representative photomicrographs of rat aortic rings after 9 days in culture medium 
containing 5% control medium, 5% BMSC-CM or 20 ng/ml of rat VEGF. 
(B) Quantification of number of intersections (Ni) of neovessels treated with 5% control 
medium, 5% BMSC-CM and 20 ng/ml VEGF, with or without 1 µg/ml anti-VEGF.  
(C) Area below curves generated for each condition by the semi-assisted computerized 
quantification. Presence of BMSC-CM significantly favours angiogenesis and this effect is 
mediated by VEGF. Experiment was repeated 3 to 15 times. *** p <0.001.  
 
Figure 4. BMSC-CM stimulates macrophages to secrete pro-inflammatory cytokines. 
Concentration of IL-1 (A), IL-6 (B) and TNF (C) in the supernatant of macrophages 
cultured in various conditions: non-activated, activated with LPS and IFN with or without 
25% BMSC-CM, or with IL-4 and IL-13. BMSC-CM increases significantly IL-1secretion 
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by macrophages and tends also to increase their IL-6 and TNF secretion. Experiment was 
repeated 2 to 4 times. * p <0.05. 
 
Figure 5. BMSC-CM characterization by antibody arrays and ELISA. 
(A) Multiple array membrane incubated with BMSC-CM reveals the presence of hormones, 
proteases, cytokines and trophic factors. Experiment was repeated 3 times.  
(B) Concentrations of NGF, BDNF and IL-6, measured by ELISA, within BMSC-CM. 
Experiment was repeated 2 to 13 times. 
 
Figure 6. Behavioural analysis. 
Evolution of motor scores for BMSC-CM treated and control rats over 6 weeks, as assessed 
(A) by BBB scale and (B) by grid navigation scale. BMSC-CM treated rats obtained 
significantly higher scores compared to control animals. 10 animals per group were studied. 
*** p <0.001. 
 
Figure 7. BMSC-CM reduces lesion extension.   
(A) Illustration of an injured spinal cord transversal section invaded by a cyst. For each 
section, cystic cavity extent (H1) and spinal cord extent (H2) were measured on the median 
axis. Both values were related to express a ratio in percents.  
(B) Photomicrographs of Luxol-fast-blue / periodic acid - Schiff / hematoxylin stained 
sections of BMSC-CM treated and control animals, taken at the lesion epicentre, 6 weeks 
after injury. Cyst extent is shown by an arrow.  
(C) Ratio cyst extent / spinal cord extent of BMSC-CM treated and control animals, 6 weeks 
after injury. BMSC-CM treated animals obtained a ratio significantly reduced compared to 
control group. 6 animals per group were studied. ** p <0.01. 
 
Figure 8. BMSC-CM increases blood vessel diameter within the lesion.  
(A) Mean blood vessel diameter at the lesion epicentre measured on RECA-1 immunostained 
sections from BMSC-CM and control groups 1 week after SCI, illustrated in (B). Blood 
vessels in BMSC-CM treated animals have larger diameters in comparison to control animals. 






Table 1. Factors detected in BMSC-CM. 
 
Phenomena Specific properties Factors 
Apoptosis 
Anti-apoptotic 
VEGF-A, TIMP-1, CINC-3, TIMP-2, 
Osteopontin, Growth Hormone + GHR, 
EG-VEGF/PK1, TAL1A*, FGF-BP, BDNF  
Pro-apoptotic TROY, TRAIL, Fas ligand/TNFSF6  
Inflammation 
Pro-inflammatory 
TLR4 , CINC-3, Osteopontin, EG-
VEGF/PK1, CINC-2, MMP-13, MDC, Fas 
ligand/TNFSF6  
Immunomodulator Osteopontin, CXCR4, MDC  
Angiogenesis 
Pro-angiogenic 
VEGF-A, VEGF-C, Osteopontin, EG-
VEGF/PK1, TAL1A*, MMP-13, FGF-BP  




TIMP-1, CINC-3, Growth Hormone + 
GHR, BDNF  
Anti-neuritotrophic TROY  
Neuronal differentiation TIMP-2  
Modulation of neuronal activity BDNF  
Stress 
Protection from excitotoxicity and 
oxidative stress 
Osteopontin, FGF-BP  
Other 
Cell fate regulation 
TIMP-1, TIMP-2, Hepassocin, Growth 
Hormone + GHR, EG-VEGF/PK1  
Cell survival 
TIMP-1, TIMP-2, Growth Hormone + 
GHR, BDNF  
ECM modulation TIMP-1, MMP-13  
Metabolism 
Insulin degrading enzyme, Insulin, Growth 
Hormone + GHR  
 
Antibody arrays against 90 proteins were performed on 3 different samples of BMSC-CM and 
identified 23 factors likely involved in the modulation of the spinal cord injured environment. 






















N / group 
Astroglial scar 
(GFAP) 
Epicentre 7.4 ± 0.4 6.2 ± 1 0.29 - NS 4 
Rostral 5.8 ± 1.4 7.1 ± 1.7 0.6 - NS 4 
Caudal 5.4 ± 0.9 7.2 ± 2 0.46 - NS 4 
Inflammation 
(CD11b) 
Epicentre 32.1 ± 2 32.2 ± 2.7 0.98 - NS 10 
Rostral 13.1 ± 1.3 15 ± 3.2 0.57 - NS 10 
Caudal 12.1 ± 1.5 17 ± 3.9 0.25 - NS 10 
Axonal regrowth 
1 week post SCI 
(GAP-43) 
Epicentre 8.2 ± 0.9 7.3 ± 1.4 0.57 - NS 10 
Rostral 8 ± 1 7.5 ± 1.6 0.79 - NS 10 
Caudal 7.3 ± 1.1 6.9 ±1.3 0.81 - NS 10 
Axonal regrowth 
6 weeks post SCI 
(GAP-43) 
Epicentre 5.1 ± 1.2 6.2 ± 0.7 0.48 - NS 4 
Rostral 3.1 ± 1.3 4.3 ± 0.6 0.44 - NS 4 
Caudal 1.9 ± 0.6 3.1 ± 0.5 0.21 - NS 4 
Axonal regrowth 
6 weeks post SCI 
(NF) 
Epicentre 5.4 ± 1.6 6.3 ± 1.4 0.71 - NS 4 
Rostral 6.9 ± 2.5 4.8 ± 1.3 0.48 - NS 4 
Caudal 8.9 ± 3.1 6.7 ± 2 0.59 - NS 4 
 
After specific immunostainings (GFAP, CD11b, GAP-43, NF), quantifications of proportion 
(%) of stained area were performed in 3 defined areas. No statistical differences between 
treated and control rats were found.  
 
 







1: p-values and statistical tests used in experiments  
The new version of the manuscript takes into account the Reviewer’s advice and each 
"Results" section contains now a clear description of the statistical tests used and p-
values obtained.  
 
2: Conclusion about the increase of IL-6 secretion by macrophages 
The Reviewer suggests being more cautious about the conclusion of an IL-6 increase 
because only 2 samples were analysed (Fig 4B). We mention now clearly that IL-6 shows 
only a tendency to increase, as does TNF-a (Fig 4C), conferring to MSC-CM a global pro-
inflammatory action, finding reinforcing the significant increase of IL1b (Fig 4A).  (see 







1: Absence of references supporting tumour development in spinal cord after MSC 
transplantation and lack of precision. 
Text has been modified as requested by the Reviewer (see abstract and introduction).  
We now describe the disadvantages of BMSC grafts in the specific context of SCI (lack of 
differentiation and integration within the host) and we just mention that in other 
pathological contexts, BMSCs transplants have various adverse effects. Some references 
were removed, while one has been added, a review describing both the beneficial and 
the adverse effects of BMSC transplantation in various pathological models (Wong R, 
2011). 
 
2: Differences between our previous published study and this work. 
 
- The Reviewer noticed that the control group in the present study has a better 
spontaneous recovery than the BMSC-transplanted group from our previous 
study (Quertainmont et al., 2012). We agree and can explain this difference 
between studies by the fact that the lesion models used in each study are not the 
same: compression injury in Quertainmont’s study, and contusion injury in the 
present study. In the new version of the manuscript, we are more cautious in our 
comparisons and text has been adapted in accordance with this (see Discussion).  
 
- The Reviewer asked if the observers performing behavioural tests were blinded 
to the type of therapy. This was the case, and was already mentioned in the 
“Material & Methods” section of the original version (point II.8). 
 
Response to Reviewers
- The Reviewer noticed a divergence between grid navigation scales described in 
"Materials and Methods" section (mentioned as a 6-point scale) and the graph 
presented in the “Results” where a 5-point scale is illustrated. Indeed, there is a 
mistake in "Materials and Methods" section, and correction has been made. (See 
Material & Methods, point II.8). 
 
- Moreover, Reviewer asked that we explain why, in the grid navigation test, we 
use in the current study a 5-point scale and in our previous study a 4-point scale. 
The 5-point scale is a little bit more precise and has been published later than the 
scale used in our previous work (4-point scale). Both scales have been used in the 
literature. 
 
Details of each score for 4-point scale (from Gaviria et al., 2002): 
0: hindlimb drag; no foot placement 
1: consistent foot faults; foot misses wire and falls through mesh 
2: consistent foot faults; foot slips off wire after accurate step and falls through mesh 
3: accurate foot placement on wire but toes do not grip 
4: normal course over the grid with toes gripping wire 
 
Details of each score for 5-point scale (from Perrin et al., 2010): 
0: no foot placement 
1: feet miss and fall in the hole 
2: feet try a placement on the grid but can't perform it 
3: after accurate step, feet slip off grid and fall 
4: accurate foot placement but toes do not grip 
5: normal course 
 
- No data from injured-only rats were mentioned, because this control has not 
been done in the study, as no differences between our 2 controls were found in 
the previous study by Quertainmont. This is also justified by the fact that our aim 
was to assess the effect of MSC-CM after SCI. The more appropriate control was 
thus to compare treated rats with a group of animals submitted exactly to the 
same experimental protocol (anaesthesia, injury, mini-osmotic pump placement, 
solution delivery during 7 days and pump withdrawal) with the sole difference 
being the content of the solution delivered by the pumps: MSC-CM or control 
medium (same composition as the medium used for MSC cultures). Thus, if 
differences between groups were observed, they could only be attributed to the 
conditioned medium.  
 
3: Factors known to be secreted by BMSCs are not detected in the present study. 
The Reviewer advised us to contrast our findings with similar studies since we do not 
detect in the BMSC-CM some factors already described as being secreted by BMSCs. 
We have followed the suggestion of the Reviewer and have adapted the text in the 
discussion section. 
 
4: Stability of factors continuously delivered during 1 week in vivo 
The Reviewer suggests that we discuss the stability of growth factors that are 
continuously delivered during one week, and how we can prove that their effects are 
maintained when implanted in vivo. 
In the first version of the manuscript, we didn't mention that we assessed the stability of 
our MSC-CM in order to be sure that it would keep its effectiveness when used in vivo 
for 7 days. In this purpose, we have compared the anti-apoptotic effect of MSC-CM (i) 
freshly defrosted or (ii) kept for 7 days at 37°C, on neurons using the protocol described 
in the manuscript. No differences were seen between the 2 MSC-CM, comforting us in 
the fact that MSC-CM preserves its properties at least 7 days at 37°C. This is now 
explained in "Material & Methods" and ‘Results” sections.  
 
 
5: Description of BMSC-CM preparation and justification of proportion used in in vitro 
experiments 
The Reviewer would like that we describe more precisely the generation of conditioned 
medium as it is the primary material investigated in our study. He also asked to explain 
why different concentrations of BMSC-CM were used among in vitro experiments.  
 
We have followed the suggestions of the Reviewer and more details are given in the 
"Materials and Methods" section (point II.1).   
- The size of culture flask is T75 (75cm2). 
- Cell number used to generate CM were not counted, but protein concentration assays 
of different aliquots of BMSC-CM were performed. We always obtained a concentration 
of 1.2 to 1.5 mg/ml. 
- CM-concentration is performed by centrifugation: starting volume of 10 ml (pooled 
CM) to obtain a final volume of 250 µl. 
- Effect of freezing was limited by defrosting aliquot of BMSC-CM only once. Also, we 
never observed any precipitate in defrosted BMSC-CM. Also, as already mentioned 
earlier, BMSC-CM keeps its properties if used after being defrosted or kept for 7 days at 
37°C. 
- The use of 25% or 5% BMSC-CM proportions for our in vitro experiments is now 
justified in "Materials and Methods" section. This choice is based on results obtained in 
pilot studies and not shown in the manuscript.  We tested 25% and 50% BMSC-CM 
proportions to assess effects on neuronal apoptosis, and obtained same results for both 
conditions.  We were also concerned to keep the highest possible proportion of nutrient 
medium (75%), to avoid apoptosis due to lack of nutriments and/or ions (KCl must be 
highly concentrated in cerebellar granule neuron medium for neuron survival).  
25% BMSC-CM was chosen for the same reasons in macrophage experiment.  
5% BMSC-CM was chosen in aortic ring experiment because this proportion already 
induced a strong angiogenic answer that would have been unquantifiable if more 
important.  
 
6: Description of passage number of BMSCs on panels C and D of figure 1 
The Reviewer asked to give the passage number of BMSCs on panels C and D for CD45 
and CD11b in BMSC characterization. Passage 4 BMSCs were used for this 
characterization by immunostaining for CD90, CD271, CD45 and CD11b. This has been 
clarified in the figure 1 legend.  
 
7: Incomplete description of multipotency in the context of SCI 
The Reviewer claims that figures 1E-F are incomplete because they do not support 
multipotentiality of our BMSCs in spinal cord injury context. The purpose of this figure is 
not to demonstrate the potentiality of cells to differentiate into cell types beneficial in 
SCI context but to characterize cells and prove that we are really in presence of BMSCs. 
Indeed, to prove that cells are actually MSCs, it is generally accepted that cells must (1) 
adhere to plastic in standard culture conditions, (2) express some markers and be 
negative for others as shown in this study and (3) have the ability to differentiate in vitro 
into osteoblasts and adipocytes. In this purpose, quantification was not necessary. 
 
8: Origin of the BMSC-CM 
The Reviewer is interested to know if BMSCs used to prepare CM derive from different 
donors. It is actually the case, and we did it to insure absence of donor-specific effects. 
BMSCs collected from different rats were pooled before seeding in T75 flasks. So BMSC-
CM harvested from these cells derived from various donors. Moreover, CM harvested 
from different flasks were pooled before concentration on centrifugal units.  
These details have been added in the first point of "Materials and Methods" section. 
 
9: Tissue sparing and remyelination 
The Reviewer writes it is difficult to assert from the figure 8B that there is a tissue 
sparing. He advised us to examine electron microscopic images to conclude to a sparing 
of the tissue and a better remyelination. 
- Figure 8B shows lesioned spinal cord sections immunostained for RECA-1 to 
reveal blood vessels. This figure is thus not useful to assess for any remyelination 
or tissue sparing.   
- Probably, the Reviewer made reference to figure 7B that shows 
microphotographies of spinal cord tissue sections stained with Luxol-fast-blue / 
periodic acid - Schiff / hematoxylin. This figure shows clearly that the ventro-
dorsal extension of the lesion is significantly lower in treated animals compared 
to controls. It is important to note that these quantifications were made on 
sections from the lesion epicentre, where the injury is the worse, and thus, the 
more tissue preserved, the better recovery will be possible. 
Finally, remyelination is a parameter that we didn't mention nor quantify in our 
manuscript. This is why electron microscopy was not used. 
 
10: Number of replicates.  
The Reviewer suggests indicating more clearly the number of replicates performed in all 






- The sentence "and which constitutes the called" in the "Introduction" section has 
been rephrased. 
 
 
 
 
 
